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1.1 BACKGROUND AND AIM OF PROJECT 
The ischemia/reperfusion injury (IRI) of the liver is a crucial pathologic process 
encountered in several clinical situations such as hemorrhagic shock, liver resection and 
transplantation which can lead to a significant amount of liver dys-function, liver non-
function or possible mortality.1 
Despite several promising interventions both pharmacological and physical in nature, 
including antioxidant therapy, storage manipulation and pre-conditioning, there are no 
clearly established methods available to prevent hepatic IRI at present.2-5 Only through 
a better understanding of the complex ischemia/reperfusion process one can find 
interesting targets to develop new strategies to combat this serious injury. 
 
This study is aimed at using products of natural and synthetic origin to examine their 
molecular function and their impact on hepatic IRI. 
The three approaches are as follows: 
 
a. EGb 761 (Dr. Willmar Schwabe Pharmaceuticals) is a standardized extract from 
the dried leaves of the Ginkgo biloba tree. Its different constituents drawn from 
the plant offer a wide range of approved medicinal applications.6 Due to its 
diverse molecular activities affecting the redox system, microcirculation, 
mitochondrial function to name a few, EGb 761 might be an interesting 
candidate to be challenged in the multifunctional IRI process (see section 1.3). 
 
b. Dietary flavonoids have shown to have beneficial therapeutic effects, attributed 
mainly to their antioxidant capacity.7-9 Xanthohumol, the prominent flavonoid of 
the hop plant, Humulus lupulus L., and its metabolic derivative 3-
Hydroxyxanthohumol, both posses promising antioxidant properties in vitro.10, 11 
The IRI of the liver is a complex injury process driven by oxidative stress, in 
which these compounds might be interesting (see section 1.4). 
 
c. Selective NF-κB inhibition in Kupffer cells using NF-κB decoy nanoparticles is 
an approach shown to be of great value in the model of warm IR by Dr. Florian 
Hoffmann in his recent Ph.D. thesis. The cold IR model used in this case was 
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assigned as Kupffer cells are vigorously activated and as it is solely influenced 
by hepatic factors. Therefore, it is an appropriate model to specify the role of 
selective NF-κB targeting in the liver in the best possible way (see section 1.5).  
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1.2 HEPATIC ISCHEMIA/REPERFUSION INJURY 
1.2.1 Background 
At present, the ischemia/reperfusion injury (IRI) is a critical process as it has been 
recognized as significant source of morbidity and mortality in different clinical and 
environmentally induced situations.12 
In general, ischemia is caused by partial or absolute blockage of physiological blood 
flow through an organ, which results in relative deficiency of oxygen supply, leading to 
tissue injury. During subsequent reperfusion and blood flow restoration once the graft is 
reoxygenated is assumed to seriously aggravate ischemic injury.13, 14 Diseases such as 
stroke, cardiac infarction and hemorrhagic shock as well as surgical interventions such 
as liver resections, coronary bypass surgeries and whole organ transplantations are the 
main processes in which IRI occurs.15 
Moreover, the use of marginal grafts for transplantation, due to an insufficient supply of 
available organs for transplantation, renders them to be more susceptible to ischemia 
followed by reperfusion.1, 5 Subsequently, that leads in a noteworthy amount to organ 
dys-function or even non-function of the grafts, thus aggravating organ shortage. 
The liver belongs to the most frequently transplanted organs. In up to 10 % of early 
organ failure the IRI phenomenon is involved.5 Hence, to achieve new insights in 
possible treatment strategies, a better understanding of the molecular pathophysiology is 
of great value. 
 
1.2.2 Model differentiations 
In general it has to be distinguished between two different clinical models of IRI. 
During surgical liver interventions, when low blood flow stops or whole perfusion 
interruptions are unavoidable to prevent excessive bleeding (e.g. during liver 
resections), the warm ischemia/warm reperfusion (warm IR) event occurs. It is often 
referred to as the so-called Pringle’s maneuver. Characteristically, the liver temperature 
is kept on the physiological body temperature during the whole process, i.e. 37 °C. 
In contrast, in the cold ischemia/warm reperfusion (cold IR) model the temperature is 
reduced after harvesting the liver and kept at 4 °C during the transport of the organ to 
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the recipient. The ischemic storage period can last for up to several hours, while the 
graft is stored at 4 °C in different solution media (e.g. University of Wisconsin (UW), 
Euro-Collins, Ringer), which contain several ingredients to mimic physiological blood 
composition and exert beneficial activities on the injury outcome.3 
The impact of model differences regarding the injury outcome and general cellular and 
molecular mechanisms are mentioned in detail in the next section. 
 
1.2.3 General mechanisms 
The exact molecular mechanisms that lead to hepatic IRI are complicated and the 
underlying biochemical pathways of this phenomenon remain unclear. So far, in 
literature two distinct injury pathways are discussed. First, the injury caused by the 
ischemic period, second, the damage induced by reperfusion of the liver graft (Figure 
1).16 
 
ISCHEMIA 
The ischemic period due to tissue anoxia leads to disturbance of the mitochondrial 
respiration. Followed by the depletion of intracellular ATP and deterioration of energy 
dependent metabolic processes, which display the hallmark of ischemia.13 
Subsequently, anaerobic pathways are favored, which result in cellular acidosis and 
tissue damage.3, 16 Moreover, the failure of active transmembrane transport of the 
mitochondria follows an imbalance of intracellular ion status, resulting in endothelial 
and Kupffer cell swelling followed by narrowing of the sinusoidal lumen.17, 18 Low 
temperatures during cold ischemia have shown to attenuate ischemic tissue damage, as 
the metabolic rates are significantly reduced and important metabolic functions could be 
maintained for longer periods.3 However, experimental evidence suggested that 
sinusoidal endothelial cells (SEC) are more susceptible when subjected to hypothermic 
ischemia.18, 19 The release of several proteases cause SEC detachment from the 
underlying hepatocytes.3 Thus, the UW solution, which is at present the preferred 
storage solution, is assumed to be effective in attenuating cold ischemic liver injury, due 
to its protease inhibitor content.3 Despite, SEC suffer seriously from the hypothermic 
period and are more vulnerable following reperfusion.18 In contrast, during the warm 
ischemic period, hepatocytes are discussed to be the preferential cell-type susceptible.19 
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The release of non-lysosomal proteases (e.g. calpains) might be the causative factor. 
Meanwhile, calpains demonstrated to be involved in both the warm and the cold 
ischemic period. 20, 21 Indeed, hepatocellular injury during the cold ischemic period is 
rather mild.22 
 
 
REPERFUSION 
The second injury pathway manifests itself when the ischemic liver is reperfused. 
Paradoxically, restoring the blood supply is assumed to be the more prominent injury 
pathway of IR, which is characterized by an excessive inflammatory response. It is 
reported that this pathway consists of two phases, depending on the duration of 
reperfusion. The initial (acute phase) and the late phase (subacute phase).16, 23 
Indeed, both phases cannot be separated clearly as they merge seamlessly. 
 
INITIAL PHASE 
Within the first 6 hours of reperfusion the resident liver macrophages, the Kupffer cells 
(KCs), are assumed to be mainly involved in the pathomechanism leading to an 
excessive inflammatory response.16, 24 
The liver consists of several cell-types. Hepatocytes, also referred to as parenchymal 
cells, account for 65 % of all liver cells. Non-parenchymal cell-types are endothelial 
cells, hepatic stellate cells and Kupffer cells. Kupffer cells contribute to 15 % of the 
liver cells and represent the greatest amount of macrophages of any organ in the whole 
body. They reside in the hepatic sinusoids, the area of blood flow circulation, and 
constitute the first macrophage population of the body exposed to pathogens of 
gastrointestinal origin (bacteria, bacterial endotoxines and microbial debris). Therefore, 
they represent a main component of the innate immune system.24, 25 
Their activation during the initial phase of IR causes the release of large amounts of 
reactive oxygen species (ROS; see section 1.2.4) and leads to the activation of the 
proinflammatory transcription factor NF-κB (see section 1.2.5), resulting in the 
excessive secretion of proinflammatory cytokines, in particular TNF-α, IL-1 and IFN-
γ.24, 25 As described in the according sections, various pathways result in tissue injury 
following ROS release and NF-κB activation. Interestingly, cold ischemia implicates a 
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more dominant Kupffer cell activation following reperfusion compared to livers which 
underwent warm ischemia.15 
Furthermore, the release of the platelet activating factor (PAF), which mainly derives 
from KCs, might play a crucial role already in the initial phase. It upregulates neutrophil 
recruitment, which is actually assumed to be the hallmark of the late phase of 
reperfusion.26 However, their adherence to the activated Kupffer cells contributes to 
plugging of the sinusoidal vessels which results in microcirculatory failure.27 
Moreover, CD4+ T-lymphocytes are activated early after reperfusion resulting in the 
release of several acute phase proteins (e.g. IL-17, IFN-γ), which activate KCs and 
stimulate neutrophil recruitment as well.28 Similar effects are proposed for the 
complement system, as inhibition of several complement factors (e.g. C1-INH, sCR1, 
C5aR) reversed these effects.29  
 
LATE PHASE 
The late phase starts approximately 6 hours postreperfusion and is characterized by the 
massive accumulation of neutrophils in the sinusoids.16 Multiple processes are taking 
place, in which chemokines (e.g. CXC) are released by activated endothelial cells which 
induce the recruitment of neutrophils into the sinusoidal vessels. The expression of 
selectins (e.g. E-selectin) on the surface of endothelial cells enables interactions with 
their counterparts on neutrophils.27 Moreover, intracellular adhesion molecules (e.g. 
ICAM-1) expressed on hepatocytes and on the endothelial cell-surface interact with 
integrins (e.g. Mac-1, LFA-1) on the surface of neutrophils, which leads to firm 
adhesion. Finally, adhered neutrophils transmigrate from the sinusoidal side into the 
hepatic parenchyma leading to hepatocyte degranulation and long-lasting oxidative 
stress, due to the release of proteases (e.g. elastase, cathepsin G) and ROS, 
respectively.30 Beside its direct impact on hepatocellular injury, the adhesion and 
plugging of neutrophils and platelets within the sinusoidal vessels can obstruct the 
lumen, which leads to microcirculatory disturbances of the blood flow, aggravating 
parenchymal tissue injury even further.13 
Moreover, several other factors shall accompany in neutrophil recruitment such as IL-
17 release by CD4+ T-lymphocytes and complement factors which function as 
chemoatractants and prime neutrophils for ROS formation.28, 29 
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Figure 1 Putative mechanism of IRI in the liver. 
 
1.2.4 Role of ROS 
Reactive oxygen species (ROS) play a pivotal role in the hepatic IRI as they are 
released mainly during reintroduction of oxygen, thus early after reperfusion of the 
ischemic liver. Physiologically, ROS are either by-products generated of several 
processes (e.g. ATP generation, protein + lipid degradation) or second messengers 
controlling cell fates and inflammation.14 
 
OXIDATIVE STRESS 
A complex system of endogenous enzymatic (e.g. CAT, SOD, GPx) and non-enzymatic 
(e.g. GSH, α-tocopherol, ascorbic acid) redox degrading antioxidants keep ROS on 
physiological harmless levels. During pathological situations such as IR, ROS levels 
exceed the endogenous capacities of removal, resulting in oxidative stress.2, 31 
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ROS are generated in the liver during IR by different sources such as enzymes, 
organelles and specific cell-types, in particular phagocytes, which interdependently 
contribute to oxidative stress. The main intracellular sources are mitochondria, which 
predominantly generate ROS right after the onset of reperfusion within the respiratory 
chain. The xanthine-oxidase (XO), derived from conversion of xanthine-dehydrogenase 
during ischemia, is another intracellular source as well as activated NAD(P)H oxidases. 
Both enzymes generate ROS in several cell-types such as Kupffer cells, neutrophils, 
endothelial cells and hepatocytes. Eventually, the extracellular release of ROS by KCs 
is responsible for vascular oxidative stress in the sinusoid. Moreover, neutrophils 
contribute indirectly to oxidative stress after transmigration and adherence to the 
parenchyma. In conclusion, oxidative stress during IR evolves collectively from several 
pathways (Figure 2).14, 15, 32 
However, it should be mentioned that superoxide anion radicals are also generated in 
low levels during the ischemic period in mitochondria within respiration, as total anoxia 
is unlikely, thus low molecular oxygen levels for radical formation still exist. Although 
its role in ischemia is not definitely clarified, beneficial effects for signaling pathways 
and cell adaptation are discussed.14  
 
 
Figure 2 Sources of ROS generation (red) vs. endogenous antioxidants (green). 
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DETRIMENTAL EFFECTS 
Different pathways are leading to detrimental effects, as ROS affects the cellular system 
directly and indirectly (Figure 3). ROS react with important cellular components such 
as nucleic acids, polyunsaturated lipids and proteins. Membrane damage due to lipid 
peroxidation (LPO) is assumed to be a critical factor, as it is associated with loss of ion 
homeostasis followed by cell swelling. Moreover, mitochondria are particularly 
susceptible to oxidative damage, forming membrane permeability transition pores, 
which result in the breakdown of the membrane potential and in the release of 
substances such as cytochrome C, apoptosis-inducing factor and others. Subsequently  
the caspase cascade is activated which causes cell death. Furthermore, ROS are 
implicated in the activation of the platelet activating factor (PAF) and in the generation 
of proinflammatory cytokines, chemokines and adhesion molecules, primarily by 
activation of redox sensitive transcription factors, like NF-κB and AP-1.15, 33 
Ultimately, cellular damage and death of hepatocytes and endothelial cells are 
unescapable results.  
However, postischemic ROS generation is also assumed to induce beneficial pathways 
such as upregulation of heme oxygenase-1 (HO-1) expression or indirect inhibition of 
ROS generating NAD(P)H oxidases.32 
 
 
Figure 3 Reactive oxygen species (ROS) affect different pathways with detrimental outcome. 
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NITRIC OXIDE 
The major ROS, which are important in hepatic IRI include the superoxide radical    
(O2.-), hydroxyl radical (HO.) and hydrogen peroxide (H2O2). Additionally, some 
reactive nitrogen species (RNS) like nitric oxide (NO.) and the strong oxidizing agent 
peroxynitrite (ONOO-) are crucial in the oxidative stress induced tissue injury.34 
The enzyme family nitric oxide synthetases (NOS) generate NO by catalyzing the 
oxidation of L-arginine to L-citrulline (Figure 4). Its role for the aggravation of liver 
damage remains controversial, as low amounts of NO generated by the constitutively 
expressed isoform endothelial NOS (eNOS) have been assumed to be responsible for 
blood flow regulation, since it functions as potent vasodilator by activation of guanylate 
cyclase (GC).35 In contrast, IR induces the generation of high NO amounts by the 
inducible NOS (iNOS), which react with superoxide anion (O2.-), followed by forming 
the high-potent reactive nitrogen species peroxynitrite. Hence, injury is primarily 
aggravated, by the predominance of the detrimental peroxynitrite and further on by 
general systemic effects due to high NO amounts leading to hypotension and shock.1 
Alternatively, Jaeschke et al. proposed that ROS contribute to microcirculatory failure, 
as the withdrawal of NO for peroxynitrite generation induced a shortage of 
vasodilators.32 However, selective iNOS inhibition was reported several times to have   
beneficial effects in IRI. 36-38 In contrast, selective eNOS inhibition or eNOS gene 
knockout mice reduce microvascular perfusion, hence, worsening of tissue injury.39, 40 
 
Figure 4 NO generation by eNOS and iNOS. 
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In that context endothelin-1 (ET-1), a potential vasoconstrictor released during the 
reperfusion period, also affects microcirculation of the liver tissue.17 Interestingly, 
hepatic microcirculation has shown to correlate inversely with ET-1 levels, suggesting 
that microcirculatory failure is, at least in part, mediated by ET-1.41 Moreover, an 
upregulation of the endothelin B receptor during reperfusion contributes to elevated 
sensitivity for endothelins, thus, receptor antagonists have shown to diminish IRI.1 
 
ANTIOXIDANT THERAPY 
The balance between detrimental and beneficial effects of ROS has to be kept in mind 
when oxidative stress driven diseases are treated therapeutically with antioxidants. 
However, in the literature it has been shown by several studies that the treatment with 
antioxidants (e.g. NAC, α-tocopherol, ascorbic acid, SOD, GSH) as well as graft 
storage in solutions containing potent antioxidants attenuate hepatic IRI, hence, increase 
graft survival (see section 1.2.6). Moreover, gene therapy using viral and non-viral 
vectors containing genes of endogenous antioxidants are currently under intensive 
research and offer a promising tool, as conventional delivery of endogenous enzymes 
are disadvantageous due to short half-lifes and bad cellular uptake.2, 42 However, the 
pro-oxidant activities of antioxidants under certain conditions should be taken into 
account as well, when their huge protective potential is emphasized.43 
 
1.2.5 Role of NF-κB 
The nuclear factor κ-B (NF-κB) is a redox-sensitive transcription factor, which plays a 
crucial role in hepatic IRI. Beside others, the release of ROS during reperfusion in huge 
amounts activates NF-κB. Hence, antioxidant and radical scavenging approaches like 
administration of the well-known antioxidant NAC44, green tea extract45 or the delivery 
of antioxidant enzyme genes (SOD, CAT) by nanoparticles42 inhibited NF-κB 
activation and improved injury outcome markedly. 
Physiologically, NF-κB dependent genes play a central role in the regulation of the 
innate and adaptive immune response, lymphocyte function and cell survival. Studies 
indicate that NF-κB transcribed proteins are involved in T-cell proliferation and B-cell 
generation and proliferation.46 Moreover, the involvement of NF-κB in several 
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pathological conditions, like atherosclerosis47, asthma48, tumorigenesis49, heart 
diseases50 and others could be demonstrated. 
 
NF-κB ACTIVATION PATHWAY 
Intriguingly, several signal transduction pathways of different inducing mechanisms do 
converge in the single transcription factor NF-κB. Hence, NF-κB displays pleitropic 
effects during inflammation, immune response, cell survival and proliferation.51 Five 
different members can form a variety of homo- or heterodimers. p50, p52, p65/RelA, 
p68/RelB and p75/c-Rel are described to that point, whereas the p50/p65 heterodimer is 
the predominant form mediating NF-κB signaling. Usually NF-κB is non-covalently 
bound to its inhibitory proteins IκBs and retained in an inactive form in the cytoplasm, 
therefore preventing the translocation to the nucleus followed by gene transcription 
(Figure 5).  
 
 
Figure 5 NF-κB activation pathway. 
 
Certain stimuli, such as cytokines, viral and bacterial pathogens, and stress-inducing 
agents, stimulate phosphorylation of IκB via the IκB kinase (IKK). IKK is a kinase-
complex containing three tightly associated IKK polypeptides: Two catalytic subunits 
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(IKKα and IKKβ) and one regulatory subunit, the NF-κB essential modulator (NEMO), 
also referred to as IKKγ. Additionally, an alternative way of NF-κB activation is 
proposed which does not require IKK mediated phosphorylation. Indeed, both 
mechanisms result in IκB phosphorylation and lead to the ubiquitination and 
degradation of IκB by the 26S-proteasome. 
Subsequently, NF-κB translocates to the nucleus where it binds to its cognate DNA-
binding site (5’-GGGZXXYYCC-3’; Z is puine, Y is pyrimidine, and X is any base) 
within the promoter region of specific genes, where it exerts its transcriptional activity. 
The targets for transcriptional activation of NF-κB include the genes of cytokines, 
chemokines, adhesion molecules, stress response, growth factors and antiapoptotic 
regulators.22, 52, 53 
 
ESSENTIAL ROLE OF NF-κB 
Several studies attempted to inhibit NF-κB activation systematically and observed its 
indispensable function. Mice lacking p50, p52 or c-Rel show defective immune 
functions, thus confirming its essential function in the immune system.46 Moreover, p65 
knockout mice are not viable due to strong hepatocyte apoptosis.54 The treatment of 
mice with an adenoviral vector overexpressing a mutated form of IκBα (Ad5IκB), 
which is almost exclusively expressed in the liver, increased the susceptibility to 
inflammation in vivo and resulted in massive apoptosis of hepatocytes.55, 56 Transgenic 
mice containing a genetically modified, degradation-resistant IκBα transgene confirmed 
these results.57 Moreover, several approaches targeting subunits of the IκB kinase (IKK) 
complex by generation of constitutive knockout animals emphasized its essential role.58 
Eventually, it seems to be inadvisable to inhibit NF-κB in general. 
 
DUAL ROLE OF NF-κB IN THE LIVER 
The liver has a unique regenerative ability thanks to certain stimuli like inflammation, 
IRI, or liver resection. For example after partial hepatectomy of up to 70 %, hepatocytes 
proliferate and regenerate till the original liver mass is restored.  
NF-κB activation shows to be essential for hepatocyte proliferation as it induces 
antiapoptotic and proliferative protein expression.59 Recently, it was reported that the 
level of NF-κB activation in hepatocytes of IR treated livers showed a positive 
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correlation with protection.60 Whereas, NF-κB activation in Kupffer cells initially 
induces the excessive release of proinflammatory cytokines, which is assumed to 
account predominately for tissue injury.24 Moreover, NF-κB in endothelial cells is 
responsible for upregulation of adhesion molecules and chemokines, contributing to 
neutrophil accumulation and adherence.22 Therefore it is apparent that NF-κB has a dual 
role in the liver depending on the cell-type addressed (Figure 6). 
Generally, KC depletion is assumed to be the easiest method to inhibit NF-κB 
selectively in KCs. It has been shown that depletion with gadolinium chloride 
attenuated warm IRI.61 However, as mentioned above, KCs are indispensable for 
immune function, and they are necessary regulators for liver regeneration. For example, 
after liver resection KCs release the NF-κB driven cytokines TNF-α and IL-6, which 
stimulate hepatocyte regeneration and induce restoration of organ mass.62 Abshagen et 
al. recently demonstrated that regeneration after partial hepatectomy is strongly 
diminished when KCs were depleted,63 and these results were confirmed by others as 
well.64, 65 
 
Figure 6 Dual role of NF-κB activation depending on the cell-type addressed. 
 
In conclusion, the cell-type specific role of NF-κB and its essential function for liver 
regeneration have to be kept in mind when the NF-κB pathway is chosen to be 
influenced for therapeutic purposes. 
For more detailed information the reader is kindly referred to the Ph.D. thesis of Dr. 
Florian Hoffmann, as it would exceed the main interest of this thesis. 
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1.2.6 Interventions 
To counteract the burden and to reduce the adverse effects of hepatic IR, various 
strategies aimed at the different pathophysiological processes of IRI have been 
considered. These include both pharmacological approaches and physical interventions. 
 
PHARMACOLOGICAL APPROACHES 
Several antioxidants (e.g. NAC, GSH, α-tocopherol) and direct radical scavengers (e.g. 
SOD, CAT), as already mentioned above, demonstrate huge potential in different 
models of hepatic IRI. High dosages of allopurinol demonstrated to have antioxidant 
potential in hepatic IR, as it inhibits the enzyme xanthine-oxidase which participates in 
ROS generation.2 α-Lipoic acid, a well described antioxidant, has shown to regulate 
several signal-transduction pathways resulting in tissue protection. Selective iNOS 
inhibitors have proved tissue protection during hepatic IR,36, 38 as iNOS upregulation 
goes along with excessive NO production, which is linked to the formation of 
peroxynitrite and to its systematic impact on vasodilatation (see section 1.2.4). The 
pretreatment of livers suffering warm or cold ischemia followed by reperfusion, with 
the hormone atrial natriuretic peptide (ANP) reduced tissue damage and increased liver 
function, due to direct impact on several mediators of IR (NF-κB, AP-1, ROS, TNF-α 
and HSP 70).66, 67 
However, none of the above mentioned pharmacological approaches have yet found 
access to clinical usage, apart from organ storage solutions. These display a mixture of 
several constituents, which provoke in combination beneficial effects. First developed 
in the late 1980s and now the most commonly used in clinical practice, is the University 
of Wisconsin (UW) solution. The protease inhibitor lactobionate and the endogenous 
antioxidant glutathione were identified to have a main impact. Lactobionate has shown 
to reduce hypothermic cell swelling during the cold ischemic period, and strong 
antioxidant capacity has been demonstrated for glutathione.3  
 
PHYSICAL INTERVENTIONS 
The term ischemic pre-conditioning (IPC) describes the process when organs are 
exposed to repetitive brief intervals of vascular occlusion prior to sustained IR. Murry 
and coworkers described this process first for the myocardium and characterized it as an 
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adaption of the myocardium to ischemic stress.68 Meanwhile, this strategy was 
successfully applied to several organs and is used clinically as it reduces tissue injury 
and prolongs graft survival after IRI effectively. The underlying mechanism is very 
complex and not yet fully elucidated. Many factors seem to be implicated like 
adenosine, nitric oxide, oxidative stress, protein kinase C, mitogen-activated protein 
kinases, heat shock proteins and NF-κB activation.4 Interestingly, NF-κB activation was 
associated with upregulated levels of cyclin D1, a crucial regulator of cell cycle 
progression, which is assumed to account specifically for hepatic recovery.22 All these 
factors are assumed to participate in the strengthening of the liver graft resistance due to 
IPC. 
In that context, remote ischemic pre-conditioning (RIPC) is another strategy, which is 
currently under intensive research. Brief intervals of IR to an other organ distant to the 
organ which undergoes sustained IR, results in increased tolerance and tissue 
protection.12 
Heat pre-conditioning is a process in which the transplanted organ or the whole body is 
exposed to hyperthermia for a short interval before sustained IR, which results in 
increased graft survival.69 Heat shock proteins (HSPs) are assumed to be mainly 
involved, in particular HSP 70, which is closely related to stress-tolerance.  
Despite several promising interventions, there is no appropriate tool available to prevent 
hepatic IRI at present. 
 
1.2.7 Approaches of this study  
Following substances have been investigated in IRI and are discussed as listed below: 
 
a. EGb 761, kindly provided by Dr. W. Schwabe Pharmaceuticals  (section 1.3). 
 
b. Xanthohumol and 3-Hydroxyxanthohumol, synthesized by Susanne Vogel of the 
University of Regensburg (section 1.4). 
 
c. NF-κB decoy nanoparticles, provided by Sebastian Fuchs of the Department of 
Technology (section 1.5). 
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1.3 GINKGO BILOBA EXTRACT – EGB 761 
1.3.1 General aspects 
Extracts from the dried leaves of the Ginkgo biloba trees are being used for decades in 
traditional Chinese medicine. EGb 761 is a standardized extract of the Ginkgo biloba 
leaves (Maidenhair tree) kindly provided by Dr. Willmar Schwabe Pharmaceuticals and 
commercially available under the trade name Tebonin in different pharmaceutical 
intake-forms. It has been used effectively in the treatment of several pathological 
disorders related to oxidative stress. The German Kommission E has approved its usage 
for symptomatic treatment of cerebral disorders/dementia, peripheral arterial 
insufficiency, vertigo and tinnitus (Bundesanzeiger Nr. 133, 19.7.1994). 
EGb 761 is extracted with a mixture of water/acetone giving a final ratio of 35-67:1 
(plant : extract). Its essential compounds are 24 % flavonoids (Figure 7), which are 
nearly exclusively flavonol-O-glycosides, 7 % proanthocyanidins and 6 % terpene 
trilactones, which are divided in different subgroups.6 First, the diterpenoid ginkgolides 
(3.2 %; Figure 8) and second the sesquiterpenoid bilobalides (2.9 %; Figure 9). 
Ginkgolic acids are downgraded to less than 5 ppm, since they are responsible for 
undesirable allergic effects.70 
 
 
 
flavonoid structure R1 R2 
Kaempherol H H 
Quercetin OH H 
Myricetin OH OH 
Isorhamnetin OCH3 H 
 
Figure 7  Chemical structure of flavonoid glykosides (24 %) in EGb 761. 
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ginkgolide R1 R2 R3 
A OH H H 
B OH OH H 
C OH OH OH 
J OH H OH 
Figure 8  Chemical structure of ginkgolides A, B, C and J (approx. 3.2 %) in EGb 761. 
 
 
Figure 9 Chemical structure of bilobalides (2.9 %) in EGb 761. 
 
1.3.2 Molecular activities 
The molecular mechanism and therapeutic benefit of the complex Ginkgo biloba 
extract, EGb 761, is versatile, since its effects can evolve from additive, synergistic as 
well as antagonistic properties of the different constituents. In consideration of the 
complex injury pathway of hepatic IR, EGb 761 has several promising properties, 
which could be of great value for the IR injury process. 
 
REDOX SYSTEM 
EGb 761 is a polyvalent agent capable of scavenging free radicals like superoxide 
radical, hydrogen peroxide, hydroxyl radical and nitric oxide. Their antioxidant 
activities are mainly referred to its high flavonoid glycoside content.71 Structure activity 
relationship (SAR) studies of flavonoids (Figure 7) have shown that the catechol group 
in the B-ring, the 2, 3-double bond conjugated with the 4-oxo function and the 3- (and 
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5-) hydroxyl group enable them to chelate metal ions and to scavenge directly ROS.6, 72, 
73 Contrary perspectives are given for the proanthocyanidines. On the one hand, they 
account for the antioxidant activities as direct radical scavengers, on the other hand, 
they are assumed to bind and inactivate antioxidant enzymes such as catalase and 
glutathione peroxidase.74, 75 Several studies demonstrate reduced lipid peroxidation after 
subjection to IR when treated with EGb 761 before.76 Interestingly, the activities of the 
endogenous enzymatic (SOD, GPx) and non-enzymatic (GSH) antioxidants were shown 
to be upregulated by EGb 761 treatment in different models. Additionally, the induction 
of mitochondrial SOD expression and heme oxygenase-1 (HO-1), as seen in microarray 
analysis, further supports this relationship.6, 76, 77  
 
MICROCIRCULATION 
The ginkgolides (A, B and C) have shown to inhibit platelet activation and aggregation, 
as they are potential PAF-receptor antagonists,6, 78 thus influencing blood rheological 
properties and circulation positively. Interestingly, on oxidative stress induced 
aggregation ginkgolides had no impact, although the whole extract (EGb 761) inhibited 
platelet aggregation. That confirms that ginkgolides exert their activities without major 
impact on oxidative stress.79, 80 Recently, Zhang et al. show that EGb 761 treatment in 
chronic liver injury improves hepatic microcirculatory and prevents sinusoidal 
endothelial cell damage.41 Interestingly, the amount of ET-1, a potent vasoconstrictor, 
was significantly reduced, suggesting that ET-1 inhibition via EGb 761 is, at least in 
part, responsible for the improvement of microcirculation. Myeloperoxidase (MPO), an 
indicator of neutrophil accumulation, was reduced after EGb 761 treatment in different 
IR models. Moreover, sinusoidal microcirculation was significantly improved by EGb 
761 pre-treatment prior to hepatic warm IR, which goes along with reduced leukocyte 
adherence in postsinusoidal venules.81 
 
MITOCHONDRIAL FUNCTION 
It is well-known that impairment of mitochondrial function occurs mainly during the 
ischemic period and results in ATP depletion (see section 1.2.3). Moreover, 
mitochondria are very susceptible to radicals, hence, the potential of EGb 761 to 
scavenge radicals protects the mitochondria indirectly. 
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Bilobalides are considered to be crucial for neuroprotection and have shown to be 
responsible for the reduction of cerebral damage after ischemia, as they improve 
cerebral energy metabolism by stabilizing mitochondria. Interestingly, increasing 
evidence emerges, that EGb 761 and in particular the bilobalides exert protective effects 
on the mitochondrial respiratory chain. Janssens and colleagues revealed that the 
respiratory chain activity is kept on high levels during ischemia when treated with 
bilobalides, thus preserving the ATP pool and limiting tissue damage induced by 
ischemia.82, 83  
 
NF-κB SIGNALING 
As mentioned above, the transcription factor NF-κB is crucial in hepatic IR. Since NF-
κB is redox regulated, it was proposed that its inhibition in myocardial IR with EGb 761 
is mainly due to ROS reduction.84 Moreover, the inhibition of iNOS activation by EGb 
761, as seen in different inflammatory models (LPS; LPS/IFN-γ) and in myocardial IR, 
respectively, was linked to the blockage of NF-κB activation.85-87 In addition, attenuated 
TNF-α levels after Ginkgo biloba extract treatment confirm the impact on NF-κB, as 
this cytokine is NF-κB regulated.86 
 
1.3.3 Experimental outline 
This project aimed to elucidate the impact of the Ginkgo biloba extract, EGb 761, on 
the complex hepatic IR model. Therefore, following aspects were mainly considered: 
 
 Effect on hepatic tissue injury. 
 
 Impact on acute arterial blood pressure. 
 
 Evaluation of eNOS expression in vivo. 
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1.4 XANTHOHUMOL AND 3-HYDROXYXANTHOHUMOL 
1.4.1 General aspects 
The principal prenylated flavonoid of the hop plant, Humulus lupuls L., is Xanthohumol 
(XN), which constitutes approximately 82-89 % of the total amount of prenylated 
flavonoids of different hop varieties.88 Xanthohumol (Figure 10) is characterized by an 
open C-ring flavonoid structure, a so-called chalcone. Chalcones are one of six major 
subgroups of flavonoids that are found in most higher plants. In plants, flavonoids are 
bio-synthesized through the phenylpropanoid pathway leading after the first committed 
step to chalcones.89 
 
 
Figure 10 Chemical structure of Xanthohumol (XN). 
 
Hop preparations are well-known in medicine for treatment of sleeping disorders as 
tranquilizer or for the activation of gastric function as bitter stomachic.90 The German 
Commission E approved hops for the treatment of mood disturbances, such as 
restlessness and anxiety as well as sleep disturbances (Bundesanzeiger Nr. 50, 
13.3.1990). In recent years, hop has attracted considerable interest since its constituent 
Xanthohumol was identified as broad-spectrum anti-cancer and chemopreventive 
compound.91 
Beer is one of the most commonly consumed alcoholic beverages, and hop is added for 
bitterness and the typical flavor. Hence, beer is the primary dietary source of XN. 
Nevertheless, the concentration of XN in beer is very low (approx. 0.1 mg/l) due to 
thermal conversion to isoxanthohumol during the brewing process.92 Moreover, orally 
administration revealed that XN is not detectable in plasma,93 thus its impact as nutrient 
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constituent might be restricted due to its poor bioavailability and its low nutritional 
content. 
Metabolic studies on human liver microsomes and feeding experiments have recently 
shown that Xanthohumol is subjected to strong biotransformation,11, 94, 95 which leads, 
among others, to 3-Hydroxyxanthohumol (OH-XN; Figure 11). OH-XN emerges from 
B-ring oxidation of XN giving a hydroxyl substituent in ortho position, which is a so-
called ortho-diphenoxyl functionality. 
 
 
Figure 11 Chemical structure of 3-Hydroxyxanthohumol (OH-XN) 
 
1.4.2 Molecular activities  
In recent years, the flavonoids Xanthohumol and 3-Hydroxyxanthohumol have shown 
promising properties primarily in in vitro experiments, which could be of interest for 
complex injury processes such as the hepatic IRI. 
 
ANTIOXIDANT PROPERTIES 
In general, it was assumed that the typical structure of flavonoids accounts for their 
antioxidant activities as they are able to scavenge ROS directly or to chelate metal ions, 
hence, preventing ROS formation as well (see section 1.3.2 Redox system).8, 96     
Beside, there is recent evidence that polyphenolics exert an indirect antioxidant effect as 
they induce endogenous antioxidant enzymes (e.g. SOD, CAT, GPx).97, 98 
Paradoxically, since antioxidants exert pro-oxidant activities in certain conditions,      
the indirect antioxidant effects of polyphenolics might be due to these contrary 
properties.97  
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Lanteri et al. recently demonstrated that treatment with the flavonoid rutin in the hepatic 
IRI is beneficial in preventing the oxidative damage, hence, reducing liver tissue 
damage after reperfusion.99 Similar studies confirmed these results for other well-
known dietary polyphenols and flavonoids such as resveratrol, epigallocatechin gallate, 
quercetin and anthocyanins, respectively.100-103 
Recent studies prove the antioxidant and free radical scavenging properties of XN in 
vitro, based on cell-free and cellular models,10, 104-107 showing higher potential than α-
tocopherol or trolox.10 Regarding OH-XN, SAR studies comparing different 
polyphenolic compounds like tea polyphenols and related phenolic compounds of 
caffeic acid phenethyl ester (CAPE), showed that a relationship between structure and 
the antioxidant activity is given, depending on the amount of hydroxyl substituents.108, 
109 In addition, the ortho-diphenoxyl functionality was shown to be also responsible for 
a better antioxidant activity as seen for resveratrol derivatives and CAPE.109, 110    
Hence, based on these data, OH-XN bears very promising structure characteristics 
compared to XN. 
Additionally, as already mentioned in section 1.2.4, the NO radical contributes to 
oxidative stress, therefore, the inhibitory effect of XN on NO production by suppression 
of iNOS expression may additionally account for its antioxidant properties.111 
Moreover, it is noteworthy to mention that polyphenolic components may affect the 
endogenous antioxidant defense potential through nuclear receptor factor 2 (Nrf2),112  
an important cellular redox dependent transcription factor. Nrf2 regulates the expression 
of several phase 2 detoxification genes. Plazar et al. mentioned that upregulation of this 
enzyme could be protective in facing oxidative stress.107 XN in particular shows to 
activate the detoxification enzyme quinone oxidoreductase, which is regulated by 
Nrf2.113  
 
INFLUENCES ON NF-κB SIGNALING 
Green tea extract (GTE), which contains high levels of polyphenols such as catechins, 
gallocatechins and epigallocatechins to name a few, has shown to inhibit NF-κB 
binding activity when rats were pretreated with GTE before hepatic IRI.45 Zhong et al. 
assumed that NF-κB inhibition with GTE is most likely due to the free radical 
scavenging activity of the polyphenols.45 Similar results were obtained for genistein, a 
Introduction 25 
 
polyphenolic flavonoid with strong antioxidant potential,114 which has shown to inhibit 
NF-κB activation in a model of cold IR subjected to IPC.115, 116  
Recently, different cancer cell models demonstrate that NF-κB activation was inhibited 
by XN.117, 118 Interestingly, Albini et al. revealed that NF-κB inhibition was associated 
with markedly decreased IκBα phosphorylation and repressed Akt protein levels, which 
is an important upstream activator of the NF-κB pathway.88  
 
These results raise the question if XN and OH-XN exert beneficial effects on oxidative 
stress driven diseases as they act simply as antioxidants or possibly through interaction 
with the NF-κB signal transduction pathway. 
 
1.4.3 Experimental outline 
This study elucidated the impact of the dietary flavonoid XN and its metabolic 
derivative OH-XN on a complex oxidative stress driven model, the hepatic IRI.           
For this purpose key-aspects were investigated as follows: 
 
 Antioxidant potential in vitro and in the liver challenged to IR. 
 
 Influence on NF-κB activation in a reportergene assay and in hepatic IR. 
 
 Impact on pro- and antiapoptotic parameters. 
 
 Consequence on hepatic tissue injury. 
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1.5 NF-κB DECOY NANOPARTICLES 
1.5.1 Background 
Interestingly, NF-κB in the liver has been assumed to have an ambiguous role 
depending on the cell-type addressed (see section 1.2.5). NF-κB activation in 
hepatocytes is reported to be essential for hepatocyte regeneration and proliferation i.e. 
cellular protection, since several antiapoptotic proteins like Bcl-2 and Bcl-xl are 
upregulated.119, 120 In contrast, the activation of Kupffer cells during IR causes an 
increase in the expression of proinflammatory cytokines leading to inflammation and 
liver failure.3, 24 However, the role of NF-κB in Kupffer cells is more complicated as 
they also trigger the regeneration of hepactocytes indirectly due to the release of      
TNF-α and IL-6.62 Therefore, selective and transient NF-κB inhibition in Kupffer cells 
is a more promising approach than persistant NF-κB inhibition.60, 120 That is confirmed 
by several studies, as unspecific NF-κB inhibition in the liver and general depletion of 
the Kupffer cells, respectively, affects negatively hepatocyte regeneration and 
proliferation following hepatic IR and impairs the physiological functions of Kupffer 
cells.54-56, 63-65 
 
1.5.2 Targeting Kupffer cells 
The challenge is to find an appropriate carrier, which enables exclusive transport to the 
liver resident macrophages, the Kupffer cells. 
Liposomes were used as a promising approach as different substances can be 
encapsulated or bound to their surface and are taken up by Kupffer cells,121, 122 but they 
are highly unselective as they tend to fuse with several cell-types.123 Moreover, other 
carriers have shown insufficient selectivity as they are transported to endothelial cells as 
well or as they also result in a high inflammatory response, e.g. when adenoviral gene 
transfer is used.124-126 
Dr. Florian Hoffmann described in his recent Ph.D. thesis for the first time a Kupffer 
cell specific carrier based on gelatin NP, which enables exclusive delivery of NF-κB 
decoy oligodeoxynucleotides to KCs without affecting NF-κB in hepatocytes or other 
cell-types, NF-κB decoy-NP. 
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NF-κB decoy-NP consist of positively charged gelatin NP, which interact ionically with 
negatively charged double-stranded oligonucleotides (ODN), encoding for the 
consensus sequence of the NF-κB promoter region (Figure 12). 
 
 
Figure 12 Ionic interactions between negatively charged decoys and positively charged NP results 
in decoy-NP. 
 
Hence, the transcription factor NF-κB is selectively bound by NF-κB ODNs, which 
prevents binding to genomic DNA and impeds gene transcription (Figure 13). Gelatin 
NP are a selective carrier to deliver ODNs sufficiently to Kupffer cells when 
administered in vivo direct in the portal vein, as shown previously in Dr. Hoffmanns 
Ph.D. thesis. The specific size of gelatin NP (260-280 nm) and their stable, unflexible 
structure, hinders the penetration of the endothelial window (approx. 175 nm). Hence, 
the endothelial cell cover cannot be crossed. Moreover, the solid nanoparticles require a 
phagozytotic absorption, which prefers uptake by macrophages, thus, avoiding 
interaction with hepatocytes. Furthermore, gelatin is a biodegradable material, which 
limits the excessive inflammatory response as seen for adenoviral vectors and 
liposomes.126, 127 
 
For more detailed informations of gelatin nanoparticles, oligonucleotides and KC 
targeting the reader is kindly referred to the Ph.D. thesis of Dr. Florian Hoffmann and of 
Dr. Jan Zilies, as it would exceed the main interest of this thesis. 
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Figure 13 NF-κB oligonucleotide decoys interact with NF-κB avoiding gene transcription. 
 
 
1.5.3 Experimental outline 
The aim of this project was to specify the role of NF-κB in Kupffer cells. For this 
purpose, NF-κB decoy-NP were applied in the ex vivo model of hepatic cold IR.           
In order to clarify this intention, different aspects were considered as follows:  
 
 Verification of exclusive delivery to Kupffer cells ex vivo.  
 
 Impact on NF-κB activation induced by cold IR.  
 
 Role of Kupffer cell derived NF-κB on the hepatic injury.  
 MATERIALS AND 
METHODS 
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2.1 MATERIALS 
2.1.1 Ginkgo biloba extract – EGb 761  
2.1.1.1 SOLUTIONS AND REAGENTS 
Table 1 Phosphate buffered saline. 
Phosphate buffered saline (PBS; pH 7.4) 
NaCl 123.2  mM 
KH2PO4 3.16 mM 
Na2HPO4 10.4  mM 
H2O  
 
2.1.1.2 GENERAL ASPECTS  
EGb 761 is a well-defined, standardized preparation of the dried Ginkgo biloba leaves 
and was kindly provided by Dr. Willmar Schwabe Pharmaceuticals. The composition, 
therapeutic uses and molecular functions are described in section 1.3. The chemical 
structures of the main constitutents of EGb 761 are displayed in the same section. For 
experiments, EGb 761 was freshly dissolved in PBS in different concentrations varying 
from 0.05 to 5 mg/ml extract. 
 
2.1.2 Xanthohumol and 3-Hydroxyxanthohumol 
2.1.2.1 SOLUTIONS AND REAGENTS  
Table 2 Solvents used for Xanthohumol or 3-Hydroxyxanthohumol. 
Solvent for cell-free or  
cellular experiments 
 Solvent for rat liver experiments  
Ethanol (96 %) 50%  Propylenglycol 4 %  
PBS   Tween 80 0.8 %  
10 mM stock-solutions were  PBS   
dissolved with PBS or DMEM medium     
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2.1.2.2 GENERAL ASPECTS 
Both compounds were kindly provided by Prof. Dr. Jörg Heilmann of the University of 
Regensburg. Detailed synthesis description and identity approval was published 
recently by Vogel et al.128 For experiments both substances were dissolved in their 
respective solvent (Table 2). The chemical structures and detailed information are given 
in section 1.4. 
 
2.1.3 NF-κB decoy nanoparticles 
2.1.3.1 SOLUTIONS AND REAGENTS 
Table 3 Reagents used for NF-κB decoy nanoparticles preparation. 
Product Company 
Gelatin type A Sigma-Aldrich 
  
NF-κB decoy oligonucleotides Biomers.net 
(5’- AGT TGA GGG GAC TTT CCC AGG C -3’,  
5’- GCC TGG GAA AGT CCC CTC AAC T -3’)  
  
Scrambled decoy oligonucleotides Biomers.net 
(5’- CCT TGT ACC ATT GTT AGC C -3’,  
5’- GGC TAA CAA TGG TAC AAG G -3’)  
  
Alexa Fluor® 488 end-labeled decoy  Biomers.net 
oligonucleotides  
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Table 4 Solutions used for NF-κB decoy nanoparticles preparation. 
KH solution (pH 7.4, 37 °C)  Rehydration at 20 nM/ml NF-κB decoy ODN 
NaCl 126 mM  Tween 80 (10 %) 34 µl 
KCl 4.7 mM  Sucrose 486.8 µl 
KH2PO4 1.2 mM  H2O 679.2 µl 
MgCl2 x 6H2O 0.6 mM  1.2 ml was dissolved freshly before 
NaHCO3 24 mM  perfusion in 120 ml of KH solution 
CaCl2 x 2H2O 1.25 mM   
Pyruvat-Na 126 mM    
Glucose 5.5 mM    
H2O     
saturated with    
95 % O2 and 5 % CO2    
 
2.1.3.2 GENERAL ASPECTS  
Preparation and loading of nanoparticles was kindly performed by Sebastian Fuchs 
(Pharmaceutical Technology, Department of Pharmacy, University of Munich). Dr. 
Florian Hoffmann (Pharmaceutical Biology, Department of Pharmacy, University of 
Munich) has previously given a detailed description in his Ph.D. thesis (2007). 
In brief, aqueous nanoparticles dispersion containing surface modified gelatin NP was 
incubated with an oligonucleotide (ODN) solution containing the sequence for NF-κB 
decoy ODN or scrambled decoy ODN, which resulted in 10 % drug loading. For 
biodistribution analysis, nanoparticles were loaded with Alexa Fluor 488 5’-end-
labeled NF-κB decoy oligonucleotides. 
For experiments, the freeze-dried gelatin nanoparticles were isoosmotic rehydrated, 
leading to a final volume of around 1.2 ml containing 20 nmol/ml NF-κB decoy ODN, 
which were dissolved 1:100 in KH (Krebs-Henseleit) buffer for animal studies. 
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2.2 CELL-FREE SYSTEM 
2.2.1 Solutions and reagents 
Table 5 Solutions and reagents used for cell-free experiments. 
Product Company 
Xanthine Sigma Aldrich 
Luminol Sigma Aldrich 
Xanthine-oxidase Sigma Aldrich 
 
Xanthine-solution                                            Luminol-solution  Xanthine-oxidase 0.5 U/l 
Xanthine 1 mM  Luminol 1 mM  Xanthine-oxidase 35 U/l 50 µl 
PBS   PBS   PBS 3450 µl 
 
2.2.2 Xanthine/xanthine-oxidase assay 
The chemiluminescence mixture was prepared immediately before analysis by mixing 
230 µl of 1 mM xanthine and 30 µl of sample. To start the reaction, 20 µl of 1 mM 
luminol and 20 µl of 0.5 U/ml xanthine-oxidase were added to the mixture, which 
contained solvent (control), XN (40 µM), or OH-XN (40 µM), respectively. 
Chemiluminescence was measured for 100 seconds at 37 °C using an Orion II 
microplate luminometer (Berthold detection systems). The results were expressed as 
relative light units (RLU) or as area under the curve (AUC). 
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2.3 CELLULAR SYSTEM 
2.3.1 Solutions and reagents 
Table 6 Solutions and reagents used for cellular experiments. 
Product Company 
Phenol-red free DMEM PAA Laboratories 
Culture flasks, plates and dishes TPP 
Fetal calf serum (FCS) Biochrom KG 
Glutamine Merck 
Dihydrofluorescein diacetate (H2FDA) Invitrogen 
TNF-α Calbiochem 
PDTC Sigma Aldrich 
 
HEK 293 growth medium  HEK 293 freezing medium 
FCS 10 %  FCS 3 % 
Glutamin 1 %  Glutamin 1 % 
DMEM phenol-red free   DMEM phenol-red free  
 
PBS Ca2+/Mg2+ solution (pH 7.4)  Trypsin/EDTA (T/E) 
NaCl 137  mM  Trypsin 0.05 % 
KH2PO4 1.47 mM  EDTA 0.20 % 
KCl 2.68 mM  PBS  
Na2HPO4 8.10 mM   
MgCl2 0.25 mM  Collagen G 
CaCl2 0.50 mM  Collagen G 0.001 % 
H2O   PBS  
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Plasmides Company 
pNF-κB-Luc, pFC-Mekk Stratagene 
pEGFP Clontech 
pβ-Gal Promega 
 
Lennox Broth (LB) Media (pH 7.2)  Lennox Broth (LB) Agar 
LB Base 2 % LB Agar 3.2 % 
H2O  
 
H2O  
 
2.3.2 Cell line and cultivation 
For experiments, cells of the human embryonic kidney cell line 293 (HEK 293; DSMZ- 
German collection of microorganisms and cell cultures, ACC 305) were cultured in a 
humidified atmosphere at 37 °C and 5 % CO2 in an incubator (Heraeus). Contamination 
of mycoplasma was routinely tested with the PCR detection kit VenorGeM (Minerva 
Biolabs). 
HEK 293 cells were grown in phenol-red free DMEM supplemented with 10 % FCS 
and 2 mM glutamine in 75 cm2 tissue culture flasks or seeded in plates or dishes for 
experiments. Therefore, culture flasks, plates or dishes were coated with collagen G for 
20 min at 37 °C before seeding. When reaching ∼85-90 % confluency, cells were 
splitted 1:4. Hence, cells were washed twice with PBS and subsequently detached by 
incubation with T/E for 2 min. Then, cells were gradually detached and centrifuged in 
PBS at 1,000 rpm for 5 min at room temperature and the pellet was resuspended in 
HEK 293 growth medium. 
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2.3.3 Dihydrofluorescein diacetate assay 
Cells were seeded in 24-well plates and when reaching ∼85-90 % confluency,        
treated for two hours with XN and OH-XN (40 µM), respectively. After 90 minutes, the       
cells were loaded additionally with 20 µM H2FDA by incubation for 30 min at 37 °C in 
the dark. Dihydrofluorescein, a ROS-sensitive fluorescence dye, is formed after 
penetrating the cell membrane and ester group cleavage. Eventually, cells were    
washed with PBS Ca2+/Mg2+ and stimulated with 1 mM H2O2 for 30 minutes (Figure 
14). 
  
 
Figure 14 Time course of HEK 293 cell stimulation for the dihydrofluorescein diacetate assay. 
  
Fluorescence was measured with a SpectraFluor Plus microplate reader (Tecan) using 
an excitation and emission wavelength of 485 nm and 535 nm, respectively. 
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2.3.4 NF-κB reportergene assay  
2.3.4.1 PLASMID PREPARATION 
The plasmid preparation was kindly performed by Andrea Rothmeier (Pharmaceutical 
Biology, Department of Pharmacy, University of Munich). 
In brief, 100 µl of competent DH5α bacteria were incubated for 20 minutes with 1-100 
ng plasmid DNA on ice. Then the bacteria were heat-shocked for 90 seconds at 42 °C 
and afterwards kept on ice. 200 µl LB-media were added and the bacteria were 
incubated at 37 °C for 30 minutes in a water bath. After incubation, up to 200 µl of the 
bacteria suspension were plated on selective (ampicillin 100 µg/ml or kanamycin 50 
µg/ml) LB-agar and incubated over night at 37 °C. 
Single colonies of transformed DH5α were picked and each colony incubated in 3 ml 
selective LB-media (37 °C) for 18 h at 150 rpm (Thermoshaker, Gerhardt). 
Subsequently, the cultured bacteria were centrifuged at 13,000 x g at 4 °C for 2 minutes 
and the mini preparation of plasmids was performed with a Plasmid MiniPrep-Kit 
(Qiagen) according to the manufacture’s description. Plasmids were cut with 
appropriate restriction enzymes and then identified by size with agarose gel 
electrophoresis after ethidium bromide staining. 
Following successful mini preparation, 3 ml of the transformed bacteria were pre-
cultivated for 8 h at 37 °C and subsequently incubated in 100 ml selective LB-media 
overnight at 37 °C and 150 rpm (Thermoshaker, Gerhardt). After centrifugation at 6,000 
x g for 15 minutes at 4 °C, the isolation was carried out with EndoFree Plasmid Maxi-
Kit (Qiagen) according to the manufacture’s protocol. 
 
2.3.4.2 TRANSFECTION OF CELLS 
HEK 293 cells were seeded at a concentration of 4 x 106 cells/100-mm dish. The next 
day, cells were transiently co-transfected with 2.8 µg of a plasmid containing 5.7-kB of 
the human NF-κB promoter driving a firefly luciferase gene (pNF-κB-Luc) and 45 µg 
of a β-galactosidase plasmid (pβ-Gal, 6.82-kB). Transfection was performed using the 
Ca2+-phosphate method for 6 hours, which is described in detail previously by Dr. 
Hans-Peter Keiss in his Ph.D. thesis (Pharmaceutical Biology, Department of 
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Pharmacy, University of Munich). For visual transfection efficiency, green fluorescent 
protein (GFP) was expressed using pEGFP transfected cells. 
 
2.3.4.3 LUCIFERASE ASSAY 
Co-transfected cells were seeded in 24-well plates at a concentration of 1 x 105 
cells/well and grown for an additional 16 hours. Then cells were pre-incubated for 2 
hours with different concentrations of XN and OH-XN (5, 10, 20, 40 and 60 µM), 
respectively, and subsequently stimulated with 1 ng/ml TNF-α for 6 hours (Figure 15). 
Cells preincubated with 50 µM pyrrolidine dithiocarbamate (PDTC) served as positive 
control. 
 
 
Figure 15 Stimulation of HEK 293 cells for the NF-κB reportergene assay. 
 
Finally, cells were washed with PBS, lysed and the NF-κB activity was measured with a 
commercial luciferase assay kit (Luciferase assay system, Promega) according to the 
manufacturer’s instructions using a luminometer (AutoLumatPlus, Berthold 
Technologies) and normalized with β-galactosidase activities to correct for transfection 
efficiency. Relative luciferase activity is expressed as the normalized luciferase activity 
in percentage of solvent treated cells (control group).  
Cells co-transfected with pFC-Mekk, pNF-κB-Luc and pβ-Gal served as negative 
control. Cells were transfected with pNF-κB-Luc or pβ-Gal alone, to eliminate 
interactions between different plasmids. 
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2.4 ANIMAL MODELS 
2.4.1 Solutions and reagents 
Table 7 Solutions and reagents used for animal experiments. 
Product Company 
Chow Ssniff 
L-NAME Cayman Chemical 
Fentanyl Janssen-Cilag 
Midazolam Ratiopharm 
Isofluran Abbott 
Carbogen  Air Liquide 
Formalin 10 % Appli Chem 
PE catheters Portex 
Heparin Braun Melsungen AG 
NORM-JECT® syringe Henke Sass Wolf 
 
2.4.2 Animals 
6 week old male Sprague-Dawley rats, weighing 200-250 g, were purchased from 
Charles River Laboratories and housed in a climatized room with a 12 hours light-dark 
cycle. The animals had free access to chow and tap water up to the time of experiments. 
All animals received human care in compliance with the „Principles of Laboratory 
Animal Care“. The study was registered with the local animal welfare committee.  
Animals were anesthetized by i.p. injection of 0.005 mg/kg Fentanyl and 2.0 mg/kg 
Midazolam. For further maintainance of anesthesia, 1.5 % Isofluran was continuously 
conducted using a vaporizer with Carbogen (5 % CO2 / 95 % O2) as a carrier gas. 
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2.4.3 Blood pressure measurement - in vivo  
2.4.3.1 SURGICAL PROCEDURE 
Blood pressure was continuously monitored with a blood-pressure gauge after 
cannulation of the carotid artery with a 16 gauge-PE catheter. 
 
2.4.3.2 TREATMENT PROTOCOL – EGB 761 
The first group received the respective solvent 30 minutes before an i.v. injection of 
EGb 761 (20 mg/kg), whereas the second group received an i.v. injection of L-NAME 
(16 mg/kg), a selective eNOS inhibitor, 30 minutes prior to the EGb 761 application 
(Figure 16). Blood pressure was monitored for 30 minutes right after EGb 761 
administration. 
 
 
Figure 16 Treatment of rats with L-NAME (16 mg/kg) or solvent, respectively, 30 minutes prior to 
EGb 761 (20 mg/kg) administration. Continuously thereafter, blood pressure was 
monitored for 30 minutes. 
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2.4.4 Warm ischemia/warm reperfusion – in vivo  
2.4.4.1 SURGICAL PROCEDURE  
The abdomen was opened by midline-laparotomy and the portal triad was prepared. 
Throughout the experiment the body temperature was maintained between 36.0 °C and 
37.0 °C with a warming lamp and blood pressure was detected as described before to 
supervise anesthesia. 
The arterial and portal blood flow to the left lateral and median lobe of the liver was 
interrupted by applying an atraumatic clip, resulting in 70 % liver ischemia. After 
ischemia, the blood supply was restored by removal of the clip and the reperfusion 
period was initiated. 
Blood samples were collected into heparinized tubes at the end of the reperfusion period 
and subsequently animals were sacrificed by bleeding. The organ was rinsed free from 
blood by perfusing the liver with PBS through the portal vein via a peristaltic pump 
(DigiStaltic from Watson-Marlow GmbH) at a flow of 55 ml/min for 2 minutes. The 
median lobe was excised and the remaining lobes were perfused with formalin 3 % in 
PBS for protein fixation. 
All tissues were cut in 3 mm cubes, immediately snap frozen in liquid nitrogen and kept 
at -80 °C until further examination. After centrifugation of blood samples at 5000 
U/min for 8 minutes, the plasma was stored in aliquots at -80 °C. 
 
2.4.4.2 TREATMENT PROTOCOLS 
2.4.4.2.1 GINKGO BILOBA EXTRACT – EGB 761  
Rats were exposed to 90 minutes of warm ischemia followed by 3 hours of reperfusion. 
Different concentrations of EGb 761 (0.2-20 mg/kg) or solvent, respectively, were 
applied intravenously via the jugular vein with a NORM-JECT® syringe 15 minutes 
before the onset of the ischemic period (preischemic). Untreated animals served as 
controls (Figure 17). 
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Figure 17 Treatment of rats with EGb 761 or solvent, respectively, prior to warm ischemia/warm 
reperfusion (1.5 h / 3 h). 
 
2.4.4.2.2 XANTHOHUMOL 
Xanthohumol (8 mg/kg) was dissolved in the respective dissolution medium and 
administered continuously with a NORM-JECT® syringe over 5 minutes via the leg vein 
preischemic, 15 minutes before the onset of warm ischemia (1 hour), and postischemic 
prior to the reperfusion period of 2 or 6 hours, respectively (Figure 18). Pre- and 
postischemic solvent administration served as control. 
 
 
Figure 18 Pre- and postischemic treatment each with 8 mg/kg Xanthohumol or solvent, respectively, 
in the cold IR model with either 2 hours or with 6 hours of reperfusion. 
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2.4.5 Cold ischemia/warm reperfusion – ex vivo  
2.4.5.1 SURGICAL PROCEDURE 
After opening the abdomen by a midline-laparotomy, the bile duct, portal vein, and 
suprahepatic inferior vena cava were cannulated with PE-catheters. The liver was 
drained and rinsed free from blood in situ with hemoglobin-free and albumin-free, 
bicarbonate-buffered Krebs-Henseleit (KH) solution (pH 7.4, 37 °C) saturated with 95 
% O2 and 5 % CO2. Additionally, the hepatic artery, the infrahepatic inferior vena cava, 
and the right kidney vein were ligated. The perfusion medium was pumped constantly 
through the liver with a peristaltic pump (Digi-Staltic from Masterflex) in a non-
recirculating fashion (30 ml/min).  
After 30 minutes of perfusion, livers were flushed with 100 ml ice-cold (4 °C) PBS 
solution, initiating the cold ischemic period. Then the perfusion was stopped and organs 
were preserved at 4 °C for 6 hours. Following the period of ischemia, livers were 
reperfused with KH buffer (pH 7.4, 37 °C) saturated with 95 % O2 and 5 % CO2 for 150 
minutes at a flow rate of 3.0-3.5 ml x min-1 x g liver in a non-recirculating fashion for 
2.5 hours. 
Perfusate samples were collected and kept at -80 °C for further transaminases and 
lactate dehydrogenase measurement. Moreover, bile production was determined 
throughout the reperfusion period and portal pressure rates were monitored on a 
hydrostatic column. Liver tissue samples were obtained at the end of reperfusion period 
and were either fixed in phosphate-buffered formalin for paraffin embedding or snap-
frozen in liquid nitrogen until analysis. 
 
2.4.5.2 TREATMENT PROTOCOLS 
2.4.5.2.1 XANTHOHUMOL AND 3-HYDROXYXANTHOHUMOL 
2.26 mM of XN (16 mg/kg) and OH-XN (16.76 mg/kg), respectively, were dissolved in 
the respective dissolution medium and filled in NORM-JECT® syringes. The chilled 
solutions (4 °C) were injected into the portal vein after liver preparation right before the 
ischemic period (preischemic) and remained in the liver during ischemia. After 6 hours 
of cold ischemia, livers were reperfused with KH buffer for 2.5 hours. Injection of the 
solution medium served as control (Figure 19). 
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Figure 19 Treatment with 2.26 mM of Xanthohumol and 3-Hydroxyxanthohumol or solvent, 
respectively, prior to cold ischemia (6 hours) followed by 2.5 hours of warm reperfusion. 
 
2.4.5.2.2 NF-κB DECOY NANOPARTICLES 
Subsequently after liver preparation, 120 ml of the KH solution containing 1.2 ml (20 
nM) NF-κB decoy-NP or scrambled decoy-NP was perfused continuously (3 ml/min) 
through the liver graft before initiating the ischemic period. Ischemia was kept for 6 
hours (Figure 20) and subsequently reperfused for 2.5 hours with KH solution.  
 
 
Figure 20 Treatment with NF-κB decoy-NP (20 nM), scrambled decoy-NP (20 nM) or solvent, 
respectively, prior to cold ischemia (6 h) followed by warm reperfusion (2.5 h). 
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2.4.5.3 BIODISTRIBUTION 
It has been shown previously by Dr. Florian Hoffmann (Pharmaceutical Biology, 
Department of Pharmacy, University of Munich) in his Ph.D. thesis that nanoparticles 
are mainly absorbed by Kupffer cells after injection in vivo. To proof the suitability of 
nanoparticle exposure in the ex vivo model of ischemia/reperfusion, 120 ml KH solution 
containing 20 nmol of Alexa Fluor® 488 labeled oligonucleotides loaded onto 
nanoparticles was perfused continuously (3 ml/min) in a non-recirculating fashion 
through the liver graft (Figure 21).  
 
 
Figure 21 Liver perfusion with NP loaded with Alexa Fluor 488 labeled oligonucleotides. 
 
Subsequently, livers were harvested right after flushing with ice cold PBS and liver 
slices were analysed by confocal laser scanning microscopy after paraffin embedding 
(see section 2.5). 
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2.5 IMMUNOHISTOCHEMISTRY 
2.5.1 Solutions and reagents 
Table 8 Products used for immunohistochemistry. 
Product Company 
Hoechst 33342 Invitrogen 
CoverplateTM Thermo Shandon 
PermaFluor® Mounting Medium Beckman Coulter 
 
Table 9 Primary and secondary antibody. 
Antibody Dilution Company 
CD 163 (MCA342R) mouse anti-rat IgG 1:100 in 0.2 % saline AbD Serotec  
 buffered BSA  
Alexa Fluor® 633 goat anti-mouse IgG 1:400 in 0.2 % saline Invitrogen 
 buffered BSA  
 
2.5.2 Staining of liver tissue 
The formalin-fixed, paraffin embedded liver sample was cut into 8 µm thick slices and 
deparaffinized in xylene following rehydration through a declining ethanol-series. The 
staining procedure was carried out using CoverplateTM disposable immunostaining 
chambers. 
For staining of Kupffer cells, sections were first incubated with a mouse anti-rat 
monoclonal CD 163-antibody overnight at 4 °C. After repeated washing with PBS, the 
secondary antibody Alexa® 633 goat anti-mouse was applied for 45 minutes. 
Subsequently, nuclei were stained with Hoechst 33342 for further 5 minutes. All 
sections were mounted with PermaFluor® Mounting Medium and analyzed by confocal 
laser scanning microscopy (LSM 510 Meta CLSM from Zeiss).  
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2.6 ANTIOXIDANT PARAMETERS 
 
The GSH and SOD level determination was kindly performed by Dr. Hussam Ajamieh 
of the Klinikum Großhadern (University of Munich). 
2.6.1 GSH 
Glutathione (GSH) levels were measured using the colorimetric microplate assay from 
Oxford Biomedical Research. Briefly, the total GSH content of the liver tissue 
homogenate is determined after reduction of DTNB (5,5`-dithiobis(2-nitrobenzoic 
acid)), causing a colored ion which absorbs light at 405 nm. This color increase is 
proportional to the total GSH concentration. The results were expressed as percentage 
of untreated controls. Protein content was determined using the Bradford method (see 
section 2.11.3). 
2.6.2 SOD 
Superoxide dismutase (SOD) activity was analyzed using the pyrogallol method 
described by Marklund et al..129 Briefly, 100 µl of the liver tissue homogenate was 
mixed with 2.8 ml of Tris-HCl (50 mM) and 50 µl of EDTA (1 mM) at pH 8.2. After 
pre-incubation for 5 min at 25 °C, the reaction was initiated by the addition of 50 µl 
pyrogallol solution with a final concentration of 0.124 mM. The change of absorbance 
at 420 nm measured after 10 seconds and 1 minute was calculated. The amount of 
enzyme, which inhibits the autoxidation rate of pyrogallol by 50 % is defined as one 
unit. The results were expressed as percentage of untreated controls. Protein content 
was determined using the Bradford method as described in section 2.11.3.  
2.6.3 MDA 
Malondialdehyde (MDA) concentration of liver homogenates was measured using the 
TBARS assay kit from Cayman Chemical. Briefly, MDA, the product of lipid 
peroxidation, reacts with thiobarbituric acid under acidic conditions at 95 °C to form a 
pink colored complex with an absorbance at 532 nm. The results were expressed as 
percentage of untreated controls. Protein content was determined using the Bradford 
method as described in section 2.11.3.  
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2.7 ELECTROPHORETIC MOBILITY SHIFT ASSAY – EMSA 
2.7.1 Solutions and reagents 
Table 10 Solutions and reagents used for EMSA. 
Product Company 
consensus binding sequence for NF-κB  Promega 
(5’-AGT TGA GGG GAC TTT CCC AGG C-3’)  
  
[γ32P]-ATP 3000 Ci/mmol Amersham 
T4 polynucleotide kinase USB 
Nuc Trap probe purification columns Stratagene 
 
Buffer A                                                                             Buffer B  Binding buffer 
Hepes (pH 7.9) 10 mM  Hepes (pH 7.9)     20 mM     Glycerol 20 % 
KCl 10 mM  NaCl 400 mM  MgCl2 5 mM 
EDTA 0.1 mM  EDTA 1 mM  EDTA 2.5 mM 
EGTA 0.1 mM  EGTA 0.5 mM  NaCl  250 mM 
H2O   Glycerol 25 %  Tris-HCl 50 mM 
add freshly before use:  add freshly before use:  H2O  
DTT 1 mM  DTT 1 mM    
PMSF 0.5 mM  PMSF 1 mM    
 
STE buffer (pH 7.5)  Loading buffer  Reaction buffer 
Tris 10 mM   
 
Tris-HCl 250 mM        Binding buffer 90 % 
NaCl 100 mM  Bromphenolblue 0.2 %  Loading buffer 10 % 
EDTA 1 mM  Glycerol 40 %  DTT 2.6 mM 
H2O   H2O   H2O  
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TBE 10 x                                                       Polyacrylamide (PAA) gel  Reaction mix 
Tris 890 mM   
 
TBE 10x 5.3 %  30 µg of nuclear 
Boric acid 890 mM  PAA solution 30% 15.8 %  protein 
x µl 
EDTA 20 mM  Glycerol 2.6 %  add after unfreezing: 
H2O   TEMED 0.05 %  poly(dIdC) 2 µl 
Dilutions  APS 0.08 %   Reaction buffer 3 µl 
were prepared with  H2O   H2O ad 15 µl 
purified water.       
 
2.7.2 Preparation of nuclear extracts 
The electrophoretic mobility shift assay (EMSA) was performed as described 
previously.130 Tissue samples were homogenized 1:10 with lysis Buffer A in a Potter S 
homogenizer from B. Braun Biotech. After centrifugation (1,000 rpm, 10 minutes, 4 °C) 
and incubation (4 °C for 10 minutes) in freshly added Buffer A, containing 6 % of 
Nonidet P-40 10 %, samples were centrifuged (14,000 rpm, 1 minute, 4 °C). The 
remaining pellet was suspended in Buffer B, followed by incubation (4 °C for 30 
minutes) under continuous shaking. After centrifugation (14,000 rpm, 10 minutes, 4 °C) 
supernatants were frozen at -80 °C. The protein concentration was determined by the 
method of Bradford as described in section 2.11.3.   
 
2.7.3 Radioactive labeling of consensus oligonucleotides 
The consensus binding sequence for NF-κB was 5’end-labeled with [γ32P]-ATP by 
incubation for 10 minutes at 37 °C using T4 polynucleotide kinase. The reaction was 
terminated by addition of 0.5 M EDTA solution and radioactive labeled DNA was 
separated from unlabeled DNA by using Nuc Trap probe purification columns. 
Radioactive oligonucleotides were eluted from the column with 70 µl of STE buffer and 
frozen at -20 °C until used for EMSA.  
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2.7.4 Binding reaction and electrophoretic separation 
The freshly prepared reaction mix, containing 30 µg of nuclear protein, was incubated 
for 10 minutes at room temperature. Subsequently, the binding reaction was started by 
adding 1 µl of the radioactive labeled NF-κB oligonucleotide. Following incubation (30 
minutes, RT), the protein-oligonucleotide complexes were separated by gel 
electrophoresis (Mini-Protean 3 form BioRad) with 0.25 x TBE buffer at 100 V for 60 
minutes using non-denaturizing polyacrylamide gels.   
 
2.7.5 Detection and evaluation 
Gels were exposed to Cyclone Storage Phosphor Screens (Canberra-Packard) for 24 
hours, followed by analysis with a phosphor imager station (Cyclone Storage Phosphor 
System from Canberra-Packard). 
 
2.8 ELISA 
2.8.1 Preparation of samples 
Rat TNF-α UltraSensitive ELISA Kit was obtained from BioSource. Determination of 
serum TNF-α levels was performed according to the manufacturer’s manual. Briefly, 
after centrifugation of heparinized blood samples for 8 minutes at 5,000 rpm, the 
supernatant was separated and stored at -80 °C until further analysis.  
2.8.2 Reaction mixture  
Then 50 µl incubation buffer and 50 µl biotin conjugate were added to each 50 µl serum 
sample. Following a waiting period for 2 hours and several washing steps, the samples 
were incubated with 100 µl streptavidin coupled horse radish peroxidase (HRP) for 30 
minutes. After further washing steps, 100 µl of stabilized chromogen was added to each 
well. Finally, the reaction was terminated by adding 100 µl of stop solution. 
2.8.3 Detection and evaluation 
The absorbance was measured at 450 nm using the SUNRISE Absorbance Reader from 
TECAN. Color development was proportional to the amount of rat TNF-α in the blood. 
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2.9 WESTERN BLOT  
2.9.1 Solutions and reagents 
Table 11 Solutions and reagents used during Western blot. 
Lysis buffer  Sample buffer (SB) 5x  Stacking gel 
NaCl 150 mM  Tris-HCl 
 
 Rotiphorese  
Tris-HCl 50 mM  (pH 6.8) 
312 mM 
      Gel 30 
17 % 
NP-40 1.00 %  Glycerol 50 %  Tris (pH 6.8) 125 mM 
Desoxy-  SDS 5 %  SDS 0.1 % 
cholicacid 
0.25 % 
 DTT  2 %  TEMED 0.2 % 
SDS 0.10 %  Pyronin Y   APS 0.1 % 
H2O      (5 %) 
0.125 % 
   
add before use:  H2O    
Complete 4 mM       
PMSF 1 mM  Sample buffer (SB) 1x  Seperation gel 12.5  % 
Na3VO4 1 mM  SB (5x) 20 %  Rotiphorese 
NaF 1 mM  H2O        Gel 30 
40 % 
      Tris (pH 8.8) 375 mM 
      SDS 0.1 % 
      TEMED 0.1 % 
      APS 0.05 % 
 
Electrophoresis buffer  Tank buffer 5x        Tank buffer 1x 
Tris 4.9 mM  Tris 125 mM  Tank buffer 5x 20 % 
Glycine 38 mM  Glycine 200 mM  Methanol 20 % 
SDS 0.1 %  H2O   H2O  
H2O   
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TBS + T (pH 8.0)  Blotto 5 %        BSA 5 % 
Tris 24.6 mM  Blotto 5 %  BSA 5 % 
NaCl 188 mM  TBS + T   TBS + T  
Tween 20 0.1 %  
H2O   
 
ECL solution A        ECL solution B 
Luminol 25 mM  H2O2 0.006 % 
p-Coumaric acid 0.396 mM  Tris (pH 8.5) 100 mM 
Tris (pH 8.5) 100 mM  H2O  
H2O   
 
Coomassie 
staining solution 
  
 
Coomassie 
destaining solution  
       Ponceau solution 
Coomassie blue G 0.3 %  Acetic acid  
(100 %) 
10 %  Ponceau S 0.1 % 
Acetic acid  
(100 %) 
10 %  Ethanol (96 %) 33 %  Acetic acid 
(100 %) 
5 % 
Ethanol (96 %) 45 %  H2O   H2O  
H2O   
 
Table 12 Primary antibodies used for specific protein detection. 
Antigen Isotype Dilution  Company 
Actin mouse monoclonal 1:1000; Blotto 1 % Chemicon 
Akt rabbit polyclonal 1:1000; BSA 5 % Cell Signaling 
Phos.-AktSer 473 rabbit polyclonal 1:1000; BSA 5 % Cell Signaling 
Phos.-AktThr 308 rabbit monoclonal 1:1000; BSA 5 % Cell Signaling 
Bcl-xl rabbit polyclonal 1:1000; BSA 5 % Santa Cruz 
JNK rabbit polyclonal 1:1000; BSA 5 % Cell Signaling 
Phos.-JNKThr183/Thr185  rabbit polyclonal 1:1000; BSA 5 % Cell Signaling 
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Table 13 Secondary antibodies. 
Antibody Dilution  Company 
Goat anti-mouse IgG1 : HRP 1:1000 in Blotto 1 % Biozol 
Goat anti-rabbit : HRP 1:1000 in Blotto 1 % Dianova 
 
2.9.2 Preparation of samples 
Liver tissue (20-60 mg) was homogenized (Potter S, B. Braun Biotech) in 200-600 µl 
lysis buffer. Following centrifugation (14,000 rpm, 4 °C, 10 minutes), an aliquot of 
sample was used for protein quantification by use of the Pierce assay as described in 
section 2.11.2.  
The remaining supernatant was diluted 5:1 with 5 x sample buffer and probes were 
boiled at 95 °C for 5 minutes for protein denaturation. Samples were kept at -20 °C until 
Western blot analysis. 
 
2.9.3 Electrophoresis 
Equal amounts of protein were ensured by adding 1 x sample buffer to the respective 
probes and were separated according to their molecular weight by SDS-PAGE (Mini 
PROTSEAN 3, Biorad Laboratories). Proteins have been stacked at 100 V for 21 
minutes and were separated at 200 V for 40 minutes.  
 
2.9.4 Electroblotting 
For wet transfer, the sandwich assembly was placed in the Mini Trans-Blot Cell buffer 
tank from Bio-Rad at 100 V for 1.5 hours. Transfer sandwich was assembled in a box 
containing tank buffer (1x) starting with a wetted pad. Subsequently, a soaked blotting 
paper, the gel followed by the nitrocellulose membrane, a second blotting paper and a 
wetted pad was added. The nitrocellulose membrane (HybondTM-ECLTM, Amersham 
Biosciences) was previously activated by soaking in tank buffer (1x) for at least 30 min 
and the sandwich was assembled with the membrane facing the anode. 
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2.9.5 Protein detection 
2.9.5.1 SPECIFIC PROTEIN DETERMINATION  
To block unspecific protein binding sites, the membranes were either incubated with 
Blotto 5 % or BSA 5 % for 2 hours at room temperature. Immunological detection of 
proteins were identified by incubating the membrane with the respective primary 
antibody (4 °C, over night), followed by incubation with a HRP-conjugated secondary 
antibody (2 h, RT). After each antibody incubation step, the membrane was washed 4 
times with PBS containing 0.1 % Tween 20 for 5 minutes. All incubation steps were 
performed under gentle shaking. 
The reactive bands were visualized employing a chemiluminescent reaction by 
incubation the membrane (1 minute) with a 1:1 mixture of ECL solution A and B, 
containing luminol. The enzyme horseradish peroxidase (HRP), which is coupled to the 
secondary antibodies, catalyzes the oxidation of luminol in the presence of H2O2. 
Luminescence was detected by exposure of the membrane to an X-ray film (Super RX, 
Fuji) and subsequently developed with a Curix 60 Developing system (Agfa-Gevaert 
AG). 
β-Actin was used as loading control (Millipore). Moreover, the molecular weight of 
proteins was determined by comparison with the prestained protein ladder 
(PageRulerTM, Fermentas). 
 
2.9.5.2 TOTAL PROTEIN DETERMINATION 
Equal protein loading and blotting efficiency was ensured by staining gels as well as 
membranes with Coomassie (20 minutes, RT) or Ponceau (5 minutes, RT) staining 
solution, respectively, since all proteins were stained. Gels were extensively washed 
with Coomassie destaining solution for 30 minutes and subsequently with purified H2O 
until proteins appeared as blue bands. Moreover, membranes were washed in purified 
water until the background disappeared. 
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2.10 CASPASE-3 LIKE ACTIVITY ASSAY 
2.10.1 Solutions and reagents  
Table 14 Solutions and reagents used for caspasce-3 like activity assay. 
Lysis buffer (pH 7.5)  Substrate buffer 
Hepes (pH 7.5) 25 mM  Hepes (pH 7.5) 50 mM 
MgCl2 5 mM  Sucrose 1 % 
EDTA 1 mM  Chaps 0.1 % 
   add before use:  
   DTT 10 mM 
   Ac-DEVD-AFC 50 µM 
 
2.10.2 Preparation of samples 
Liver tissue was homogenized (Potter S, B. Braun Biotech) 1:10 with lysis buffer. 
Following centrifugation (14,000 rpm, 10 minutes, 4 °C), samples were used for protein 
quantification by Bradford assay as described in section 2.11.3. The remaining 
supernatants were stored at -80 °C until measurement. For analysis, extracts were 
incubated with the substrate buffer (1:10) containing Ac-DEVD-AFC. 
 
2.10.3 Detection and evaluation 
The generation of AFC was determined kinetically by fluorescence measurement 
(exciation: 385 nm; emission: 505 nm) using the SpectraFluor Plus microplate reader 
(Tecan). Samples containing lysis buffer were used as blank. Control experiments 
confirmed that the activity was linear with time and with protein concentration under 
the conditions described above. 
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2.11 PROTEIN QUANTIFICATION 
2.11.1 Solutions and reagents 
Table 15 Solutions and reagents used for protein quantification. 
Product Company 
BCA Assay reagents Interdim 
Coomassie Brilliant Blue BioRad 
 
2.11.2 Pierce assay  
Pierce Assay was performed as described by Smith et al..131 Samples were incubated 
1:20 with BCA Assay reagents for 30 min at 37 °C. Absorbance was measured 
photometrically with a Tecan Sunrise Absorbance reader (TECAN) at 550 nm. Protein 
standards were obtained by diluting a stock solution of Bovine Serum Albumin (BSA, 2 
mg/ml). Linear regression was used to determine the actual protein concentration of 
each sample. 
 
2.11.3 Bradford assay  
Bradford Assay was performed as described by Bradford et al..132 Samples were 
incubated 1:20 with a dilution of Coomassie Brillant Blue (1:5 in water) for 5 min. 
Absorbance was measured photometrically with a Tecan Sunrise Absorbance reader 
(TECAN) at 592 nm. Protein standards were obtained by diluting a stock solution of 
Bovine Serum Albumin (BSA, 2 mg/ml). Linear regression was used to determine the 
actual protein concentration of each sample. 
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2.12 TISSUE INJURY PARAMETERS 
Activities of serum aminotransferases (alanine transferase (ALT) and aspartate 
transferase (AST)) as well as lactate dehydrogenase (LDH) of the collected perfusates 
or heparinized serum were determined as established markes of hepatic tissue damage. 
The data were kindly provided by Babett Rannefeld from the Institute for Clinical 
Chemistry of Klinikum Großhadern, (University of Munich, Germany) using a serum 
multiple analyzer (Olympus AU 2700, Olympus) at 37 °C. 
 
2.13 STATISTICAL ANALYSIS 
Number of experiments is indicated in the respective figure legend. Data are expressed 
as mean ± SEM. Statistical analysis was performed using the GraphPad Prism 3.03 
software (GraphPad software Inc, San Diego, USA). Significance (*, #) has always 
been calculated at the 95 % confidence interval between indicated groups, using an 
unpaired t-test. 
 
  
RESULTS
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3.1 GINKGO BILOBA EXTRACT – EGB 761  
3.1.1 Impact on warm ischemia/warm reperfusion  
3.1.1.1 HEPATIC TISSUE DAMAGE  
The impact of Ginkgo biloba extract (EGb 761) was elucidated in the in vivo model of 
90 minutes warm ischemia followed by 3 hours of warm reperfusion by measuring the 
liver enzymes (AST + ALT), a parameter for hepatic tissue damage. Therefore, blood 
samples were collected at the end of reperfusion period. Pretreatment of rats with EGb 
761, in concentrations varying from 0.2 mg/kg to 20 mg/kg was not protective (Figure 
22). Instead, 2 mg/kg EGb 761 even significantly increased the liver enzymes. High 
toxic potential was observed when the concentration reached 20 mg/kg. 
 
 
Figure 22 Transaminase levels (AST + ALT) of rats treated with EGb 761 (i.v.) in different 
concentrations or with solvent, respectively, prior to 1.5 hours of warm ischemia and 3 
hours of warm reperfusion. Data are presented as mean ± SEM (n=5, *p<0.05 vs. solvent, 
#p<0.05 vs. control, Student´s t-test). 
 
3.1.1.2 APOPTOSIS  
Caspase-3 like activity of hepatic tissue was evaluated after IR, as caspase-3 is known 
to be the main effector molecule of apoptosis.133 The hepatic caspase-3 activity was 
increased in rats subjected to warm ischemia followed by warm reperfusion (Figure 23). 
Preischemic EGb 761 treatment did not alter caspase-3 increase. 
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Figure 23 Caspase-3 like activity of animals pretreated with different concentrations of EGb 761 or 
solvent, respectively, prior to warm IR. Data are presented as mean ± SEM (n=3). 
 
3.1.1.3 BLOOD PRESSURE DEVELOPMENT DURING IR 
Arterial blood pressure was monitored during the whole treatment period, starting right 
before solvent or EGb 761 application, respectively. Solvent treated animals showed 
blood pressure values around 100-110 mmHg preischemic, which tended to decrease 
during reperfusion and slightly recovered to the end (Figure 24). 
 
Figure 24 Blood pressure was monitored starting with the onset of solvent and EGb 761 (20 mg/kg) 
application, respectively, following 90 min of warm ischemia and 180 min of reperfusion. 
Data are presented as mean ± SEM (n=3, *p<0.05 vs. solvent, Student´s t-test). 
 
In contrast, blood pressure significantly collapsed straight after i.v. injection of EGb 
761 to 63 mmHg ± 6 and kept constant with minimal variations during IR (Figure 24). 
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3.1.2 Investigation of arterial blood pressure drop  
3.1.2.1 ENOS INHIBITION – IN VIVO  
In order to investigate the acute arterial blood pressure drop after EGb 761 
administration in vivo, the impact of eNOS was elucidated. The generation of NO via 
eNOS is known to be involved in blood flow regulation as it functions as vasodilator. 35 
Therefore, animals received 15 minurtes before EGb 761 (20 mg/kg) administration 
either an intravenous injection of L-NAME (16 mg/kg), a selective eNOS inhibitor, or 
the respective solvent. Arterial blood pressure was monitored for 30 minutes. Blood 
pressure dropped significantly from 115 mmHg ± 10 to 63 mmHg ± 15 straight after 
EGb 761 application (Figure 25). Thereafter, blood pressure recovered continuously. L-
NAME treatment impeded blood pressure collapse. 
 
 
Figure 25 Blood pressure of rats was monitored for 30 min after i.v. EGb 761 application. Animals 
received L-NAME (grey line) or solvent (black line), respectively, 15 min prior to EGb 
761 (20 mg/kg) application. Data are presented as mean ± SEM (n=3, *p<0.05 vs. L-
NAME + EGb 761, Student´s t-test). 
 
3.1.2.2 ENOS EXPRESSION IN ISOLATED THORACIC AORTA 
Thoracic aortas were harvested from Sprague-Dawley rats pretreated with either solvent 
or EGb 761 (20 mg/kg), respectively. WB analysis shows that EGb 761 treatment 
increases eNOS phosphorylation (Ser-1177; upper panel), compared to solvent treated 
animals (Figure 15). Total eNOS protein confirmed equal protein loading (lower panel). 
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Figure 26 Western blot analysis of solvent or EGb 761 treated animals, respectively. 
Phosphorylated eNOS (Ser 1177; upper panel) and total eNOS (lower panel). All 
experiments were performed at least three times. One representative Western blot is 
shown. 
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3.2 XANTHOHUMOL AND 3-HYDROXYXANTHOHUMOL 
3.2.1 Impact on ROS levels in a cell-free system 
The ability of the compounds to scavenge superoxide radical was evaluated by 
chemiluminescence measurement using the xanthine/xanthine-oxidase assay. 
The time course demonstrated that chemiluminescence is emitted right after luminol 
(0.66 mM) and xanthine-oxidase (0.33 U/ml) injection, peaking after approximately 8 
seconds and declining continuously thereafter (Figure 27). Chemiluminescence was 
reduced by Xanthohumol in a concentration dependent manner. 
 
 
Figure 27 Chemiluminscence light emission for different XN concentrations in comparison to 
solvent treated samples (control). One representative time course for each concentration is 
shown. 
 
When illustrated as area under the curve (AUC), XN (Figure 28) and OH-XN (Figure 
29), respectively, showed both a dose-dependent reduction in chemiluminescence, 
indicating a reduction of ROS levels. The potency for each was assessed by the dilution 
that led to 50 % inhibition of ROS detection (IC50 ). IC50 was 15 µM for XN and 25 µM 
for OH-XN, respectively. 
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Figure 28 Area under the curve (AUC) of light emission from chemiluminescence reaction for 
different XN concentrations in comparison to solvent treated controls. Data are presented 
as mean ± SEM (n=9, *p<0.05 vs. control, Student´s t-test). 
 
 
Figure 29 Area under the curve (AUC) of light emission from chemiluminescence reaction for 
different OH-XN concentrations in comparison to solvent treated controls. Data are 
presented as mean ± SEM (n=9, *p<0.05 vs. control, Student´s t-test). 
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3.2.2 Influences on the redox status in a cellular system 
Intracellular response to oxidative challenge with H2O2 was measured by loading HEK 
293 cells with 20 µM dihydrofluorescein diacetat (H2FDA). After penetrating the cell 
membrane, ester groups are cleaved by esterases, which leads to the formation of 
dihydrofluorescein, a ROS-sensitive fluorescence dye. 40 µM of XN and OH-XN, 
respectively, showed significant fluorescence reduction (XN = 71.91 % ± 9.2; OH-XN 
= 15.1 % ± 2.8) in comparison to the corresponding control (Figure 30). Moreover, OH-
XN significantly exceeds the activity of the well-established antioxidant N-
acetylcysteine (NAC; 1 mM). 
 
 
Figure 30 Fluorescence was measured of HEK 293 cells pretreated with 40µM XN or OH-XN prior  
to stimulation with H2O2. Significance was calculated at a 95 % concentration interval in 
comparison to the corresponding controls (*) and NAC (+), respectively. Data are 
presented as mean ± SEM (n=4; Student´s t-test). 
 
Results 66 
 
3.2.3 Influences on NF-κB activity in a reportergene assay 
As illustrated in Figure 31, TNF-α (1 ng/ml) induced an increase of NF-κB activity, 
which was dose-dependently reduced by pretreatment with XN and OH-XN (5 – 60 
µM), respectively. Pyrrolidine dithiocarbamate (PDTC; 50 µM) pretreatment, which 
served as positive control, reduced the NF-κB activity to 53.9 % ± 7. Interestingly, OH-
XN (IC50 13 µM) showed greater inhibitory effects than XN (IC50 35 µM). The 
capability was assessed by the dilution that produced 50 % inhibition of NF-κB activity 
(IC50). 
 
 
Figure 31 NF-κB promoter activity of HEK 293 cells treated with different concentrations of XN 
and OH-XN, respectively, prior to TNF-α stimulation. Cells treated with solvent served 
as control group and PDTC treated cells were used as a positive control. Data are 
presented as mean ± SEM (n=3, *p<0.05 vs. solvent, Student´s t-test). 
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3.2.4 Impact on warm ischemia/warm reperfusion 
3.2.4.1 NF-κB BINDING ACTIVITY  
The impact of XN on NF-κB binding activity was evaluated by EMSA of isolated 
nuclear extracts of the hepatic tissue samples. Figure 32 shows NF-κB inhibition of 
animals treated with both 8 mg/kg XN preischemic and 8 mg/kg XN postischemic, 
when subjected to 1 hour warm ischemia followed by 2 hours reperfusion. 
 
Figure 32 NF-κB binding activity was determined by EMSA of rat liver tissues harvested after 1 
hour of warm ischemia followed by 2 hours of warm reperfusion. Animals were treated 
with both 8 mg/kg XN preischemic and 8 mg/kg XN postischemic or solvent, 
respectively. Control animals were left untreated. All experiments were performed at least 
three times. One representative gel shift experiment is shown. 
 
NF-κB binding activity of animals subjected to long reperfusion periods (6 h; Figure 
33) were treated with 8 mg/kg XN, administered pre- and postischemic. NF-κB activity 
induced by IR was markedly reduced by XN treatment. 
 
Figure 33 NF-κB binding activity was determined by EMSA of whole rat liver homogenates 
subjected to 1 hour of warm ischemia followed by 6 hours of reperfusion. Animals were 
treated with both 8 mg/kg XN preischemic and 8 mg/kg XN postischemic or solvent, 
respectively. Control animals were left untreated. All experiments were performed at least 
three times. One representative gel shift experiment is shown. 
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3.2.4.2 LIVER TISSUE INJURY  
Blood samples were collected at the end of reperfusion time and were analyzed for liver 
enzymes (ALT + AST), which indicate the degree of liver injury. Animals subjected to 
1 hour of warm ischemia followed by 2 hours of warm reperfusion showed significantly 
elevated liver enzyme levels, which kept unchanged after XN treatment (Figure 34). 
 
 
Figure 34 ALT + AST levels of rats subjected to 1 hour of warm ischemia followed by 2 hours of 
reperfusion, treated with both 8 mg/kg XN preischemic and 8 mg/kg XN postischemic or 
the respective solvent, respectively. Data represent means ± SEM (n=3; #p<0.05 vs. 
untreated controls; Student’s t-test). 
 
Xanthohumol treatment did not alter the injury outcome after long reperfusion times 
either (6 hours; Figure 35).  
 
 
Figure 35 ALT + AST levels of rats subjected to 1 hour of warm ischemia followed by 6 hours of 
warm reperfusion, treated with both 8 mg/kg XN preischemic and 8 mg/kg XN 
postischemic or the respective solvent, respectively. Data represent means ± SEM (n=3; 
#p<0.05 vs. untreated controls; Student’s t-test). 
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3.2.5 Impact on cold ischemia/warm reperfusion 
3.2.5.1 ENDOGENOUS ANTIOXIDANT SYSTEM  
The levels of the endogenous antioxidants GSH and SOD were significantly reduced in 
IR subjected animals compared to untreated controls. XN or OH-XN (2.26 mM) 
administration prior to the ischemic period, respectively, reversed that decrease (Figure 
36; Figure 37).  
 
 
Figure 36 Tissue GSH levels of rats treated with 2.26 mM of XN, OH-XN or solvent, respectively, 
prior to cold hepatic IR. Control animals were left untreated. Data represent means ± 
SEM of triplicates (3 animals each group). #p<0.05 vs. untreated control or *p<0.05 vs. 
solvent (Student´s t-test). 
 
 
Figure 37 Tissue SOD levels of rats treated with 2.26 mM of XN, OH-XN or solvent, respectively, 
prior to cold hepatic IR. Control animals were left untreated. Data represent means ± 
SEM (n=3). #p<0.05 vs. untreated control or *p<0.05 vs. solvent (Student´s t-test). 
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3.2.5.2 OXIDATIVE DAMAGE  
Determination of lipid peroxidation was evaluated by quantifying the malondialdehyde 
(MDA) content with the thiobarbituric acid reactive substance (TBARS) assay. No 
differences could be observed between the untreated control animals, solvent treated IR 
group as well as the groups that received 2.26 mM XN or OH-XN, respectively, prior to 
the ischemic period (Figure 38). 
 
 
Figure 38 Tissue MDA levels of rats treated with 2.26 mM of XN, OH-XN or solvent, respectively, 
prior to 6 hours cold hepatic ischemia followed by 150 minutes of warm reperfusion. 
Control animals were left untreated. Data represent means ± SEM (n=3).  
 
3.2.5.3 NF-κB BINDING ACTIVITY  
To investigate the impact of XN and OH-XN on NF-κB DNA binding activity, the 
electrophoretic mobility shift assay (EMSA) was performed with isolated nuclear 
extracts of the heptic tissue samples. As shown in Figure 39, NF-κB activity of the 
solvent treated group is strongly increased after 6 hours of cold ischemia followed by 
reperfusion of 150 minutes with KH solution (pH 7.4, 37 °C, 95 % O2 / 5 % CO2 
saturation) when compared to untreated controls. Animals treated with 2.26 mM XN 
prior to the ischemic period revealed attenuated DNA binding activity of NF-κB, 
whereas OH-XN (2.6 mM) administration had no impact. 
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Figure 39 NF-κB binding activity was determined by EMSA of whole rat liver homogenates treated 
with 2.26 mM of XN, OH-XN or solvent, respectively, prior to IR. Control animals were 
left untreated. All experiments were performed at least three times. One representative gel 
shift experiment is shown. 
 
3.2.5.4 PROTEIN LEVELS 
Akt is described as a typical antiapoptotic kinase involved in ischemia/reperfusion 
injury.134 XN and OH-XN (2.26 mM) pretreatment, respectively, abrogated the 
phosphorylation on Ser-473 in comparison to solvent treated animals after cold IR 
(Figure 40).  
 
 
Figure 40 Hepatic protein levels of phosphorylated Akt (Ser-473; upper panel) and β-Actin (lower 
panel) by WB analysis of livers treated with 2.26 mM of XN, OH-XN or solvent, 
respectively, prior to IR. Control animals were left untreated. One representative blot is 
shown. 
 
Interestingly, the phosphorylation on position Thr-308 was markedly abolished only 
after XN pretreatment after cold IR (Figure 41). It has been shown in literature, that 
Thr-308 is the main activating event of Akt, although phosphorylation of both domains 
might be necessary for full activation of Akt.134 
Results 72 
 
 
Figure 41 Hepatic protein level of phosphorylated Akt (threonin 308; upper panel) and β-Actin 
(lower panel) by WB analysis of livers treated with 2.26 mM of XN, OH-XN or solvent, 
respectively, prior to IR. Control animals were left untreated. One representative blot is 
shown. 
 
The proteins of the Bcl-2 family exerts either pro- or antiapoptotic effects. Bcl-xl 
belongs to the group of antiapoptotic proteins.135 XN (2.26 mM) reduced the protein 
level of Bcl-xl after cold IR, when administered before the ischemic period, whereas 
OH-XN (2.26 mM) had no effect (Figure 42). 
 
 
Figure 42 Hepatic protein level determination of Bcl-xl (upper panel) and β-actin (lower panel) by 
WB analysis of livers treated with 2.26 mM of XN, OH-XN or solvent, respectively, prior 
to IR. Control animals were left untreated. One representative blot is shown. 
 
JNK activation occurs primarily in the reperfusion phase in response to ROS.22, 136 
Treatment with 2.26 mM of XN and OH-XN before the ischemic period reduced the 
protein level of phosphorylated JNK slightly after cold IR (Figure 43). 
 
 
Figure 43 Hepatic protein level of phosphorylated JNK (upper panel) and total JNK (lower panel) 
by WB analysis of livers treated with 2.26 mM of XN, OH-XN or solvent, respectively, 
prior to IR. Control animals were left untreated. One representative blot is shown. 
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3.2.5.5 APOPTOSIS  
Hepatic caspase-3 like activity was measured, as caspase-3 is known to be one of the 
main effector molecules of apoptosis.133 Caspase-3 activity was induced by cold IR 
(Figure 44). XN (2.26 mM) treatment showed an additional increase in activity, which 
was not seen after OH-XN (2.26 mM) treatment.  
 
Figure 44 Caspase-3 like activity of animals treated with 2.26 mM of XN, OH-XN or solvent, 
respectively, prior to ischemia/reperfusion. Control animals were left untreated. Data are 
presented as mean ± SEM (n=3, *p<0.05 vs. untreated control, Student´s t-test). 
 
3.2.5.6 TNF-α LEVELS 
Plasma levels of TNF-α were determined by ELISA (Figure 45). XN and OH-XN 
pretreatment, respectively, did not show significant changes compared to solvent treated 
animals. 
 
Figure 45 TNF-α levels of  perfusates were determined by ELISA, of XN (2.26 mM), OH-XN (2.26 
mM) or solvent treated animals, respectively. Data are presented as mean ± SEM (n=3). 
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3.2.5.7 LIVER TISSUE INJURY  
The perfusates were collected during the reperfusion period and LDH levels were 
determined, indicating hepatic tissue damage. Figure 46 demonstrates the time course of 
LDH development throughout the reperfusion period. LDH levels slightly decreased to 
the beginning and increased continuously to the end. XN and OH-XN pretreatment 
increased LDH levels to the end of reperfusion, although the results were not 
significant. 
 
Figure 46 Time course of LDH levels throughout the reperfusion period from rats pretreated with 
2.26 mM of XN, OH-XN or solvent, respectively. Data are presented as mean ± SEM 
(n=3). 
 
The transaminases (AST, ALT) were analyzed at the end of reperfusion (Figure 47). 
Interestingly, the XN treated group showed an obvious increase in the liver enzymes, 
whereas the levels of the OH-XN treated group remained unaltered. 
 
Figure 47 ALT + AST levels of rats treated with 2.26 mM of XN, OH-XN or solvent, respectively, 
prior to 6 hours of cold ischemia followed by 150 minutes of warm reperfusion. Data are 
presented as mean ± SEM (n=3). 
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3.3 NF-κB DECOY NANOPARTICLES  
3.3.1 Biodistribution 
Confocal laser scanning microscopy was performed to proof the suitability of decoy 
nanoparticles application in the ex vivo model of cold ischemia/warm reperfusion. Dr. 
Florian Hoffmann has already shown in his Ph.D. thesis, that decoy nanoparticles 
administered i.v. in vivo predominantly localize in hepatic tissue, moreover, selectively 
lead to colocalization in Kupffer cells. Therefore, the liver was treated with fluorescent 
labeled decoy ODNs loaded onto gelatin nanoparticles as described in chapter 2.4.5.3. 
Figure 48 displays that fluorescent labeled decoy ODNs (red) are selectively taken up 
by Kupffer cells (green), as indicated in the overlaid picture by the yellow color. No 
decoys were found in hepatocytes. 
 
Nuclei Kupffer cells Decoy ODNs Overlay 
 
Figure 48 Confocal microscopy. Blue: Nuclei; Green: Kupffer cells; Red: Decoy ODNs. The yellow 
color indicates colocalization of Kupffer cells and decoy ODNs. 
 
3.3.2 Impact on cold ischemia/warm reperfusion 
3.3.2.1 NF-κB BINDING ACTIVITY  
NF-κB DNA binding activity was elucidated with the electrophoretic mobility shift 
assay (EMSA), which was performed with isolated nuclear extracts of hepatic tissue 
samples, subjected to 6 hours cold ischemia followed by 150 minutes of warm 
reperfusion. As shown in Figure 49, ischemia/reperfusion induces NF-κB activation 
which was abolished by NF-κB decoy-NP (20 nM) treatment prior to the ischemic 
period. However, scrambled decoy-NP had no effect.  
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Figure 49 NF-κB binding activity was determined by EMSA of whole rat liver homogenates treated 
with 20 nM of NF-κB decoy-NP, scrambled decoy-NP or solvent, respectively, prior to 6 
hours of cold ischemia followed by reperfusion. Control animals were left untreated. All 
experiments were performed at least three times. One representative gel shift experiment 
is shown. 
 
3.3.2.2 LIVER TISSUE INJURY  
Perfusate samples were collected throughout the reperfusion period and transaminases 
were determined. The liver enzymes (AST, ALT) were determined after 6 hours of cold 
ischemia followed by 150 minutes of warm reperfusion. No significant changes of NF-
κB decoy-NP pretreatment could be observed, respectively (Figure 50).  
 
 
Figure 50 ALT + AST levels of livers subjected to 6 hours of cold ischemia followed by 
reperfusion. Rats were treated before the ischemic period with 20 nM of NF-κB decoy-
NP solution, scrambled decoy-NP solution or solvent, respectively. Data are presented as 
mean ± SEM (n=3). 
 
  
DISCUSSION 
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4.1 GINKGO BILOBA EXTRACT – EGB 761 
 
The standardized Ginkgo biloba leaf extract, EGb 761 from Dr. Willmar Schwabe 
Pharmaceuticals, has shown to have a multifaceted variety of molecular functions like 
antioxidant activities, vasoregulatory properties, beneficial actions on mitochondrial 
function and others, which are responsible for its therapeutic use.6 The complementary 
actions of its different constituents possibly result in additive, synergistic as well as 
antagonistic properties. Therefore, studies elucidating single ingredients of this complex 
extract do not reflect doubtlessly the effect of the whole extract. 
The pathomechanism of the hepatic IRI is very complex, resulting in severe 
hepatocellular injury. Several pathways participate in the injury cascade, such as 
mitochondrial function, redox system, sinusoidal microcirculation and the NF-κB signal 
transduction cascade. Therefore, it is difficult to achieve tissue protection by targeting 
single mediators. Hence, simultaneous interventions at several stages of this process 
could be advantageous. Thus, complex extracts offer a variety of opportunities as they 
address several molecular targets. 
Grape seed137, green tea45 and garlic extract138 have previously demonstrated to be 
protective in different models of hepatic IRI. The beneficial effects were mainly 
referred to their antioxidant potential due to the high levels of polyphenols. 
Furthermore, the literature offers a large number of studies elucidating EGb 761 in IR 
of different organs like heart84, kidneys77, bladder139, brain140, intestine141 and others, all 
demonstrating protective effects. 
Interestingly, only two studies were previously performed to evaluate EGb 761 in 
hepatic IRI, both by Gundlach and colleagues.81, 142 They revealed that intravenous EGb 
761 (20 mg/kg) administration prior to warm IR, increases the hepatic microcirculation, 
due to attenuated leukocyte adherence and plugging in postsinusoidal vessels.81 
However, classic hepatic tissue injury markers (AST, ALT) were unaltered. In our 
studies, intravenous administration of different concentrations of EGb 761 revealed that 
2 mg/kg significantly increased liver tissue damage after IR as measured by 
transaminases (Figure 22). Moreover, a further increase to 20 mg/kg EGb 761, the same 
dosage as Gundlach and colleagues used, showed an impressive augmentation of the 
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liver injury. These results indicate an enhanced toxicity of EGb 761, when given 
intravenously before warm IR. The differences to Gundlach and colleagues might be 
due to differences in the method applied, as we chose a longer ischemic period (1 hour 
vs. 1.5 hours) and a different race of rats (Lewis vs. Sprague-Dawley). The caspase-3 
like activity levels did not correlate with the levels of transaminases, instead they 
remained unchanged (Figure 23). Hence, caspases do not seem to be involved in tissue 
injury followed by IR after EGb 761 treatment.  
However, impressive acute blood pressure decrease came along with that, which could 
be a reason for impaired tissue damage. Within minutes after EGb 761 (20 mg/kg) 
administration (Figure 24), blood pressure dropped from approximately 110 mmHg to 
60 mmHg. Obviously, the blood circulation was markedly hindered right after the onset 
of reperfusion, hence, macroscopic tissue vessel thrombosis was noticed more 
frequently. Interestingly, in literature no studies described an acute arterial blood 
pressure decrease by EGb 761 or Ginkgo biloba extract treatment so far, respectively. 
Although similar dosages of EGb 761 were administrated in the same mode (i.v.), 
indeed blood pressure was never monitored,141, 143 except from three long-term feeding 
studies of Ginkgo biloba extract or EGb 761, respectively. These studies revealed blood 
pressure attenuation in hypertensive or physiologically healthy rats, respectively,144-146 
when pretreated orally. Sasaki et al. assumed that on the one hand, a decrease in 
oxidative stress reduces the withdrawal of NO for peroxynitrite formation, on the other 
hand, an increase of mRNA levels of eNOS were proposed to be responsible for 
elevated NO levels.145 Additionally, Dr. Anja Koltermann revealed in her Ph.D. thesis 
that eNOS is activated by EGb 761 treatment in vitro, which is regulated by the 
phosphoinositide 3-kinase (PI3K)/Akt pathway.  
Eventually, to investigate the underlying mechanism of acute hypotension and the 
involvement of eNOS in this process, a selective inhibitor of eNOS was given in vivo 
before EGb 761 administration. As seen in Figure 25, eNOS inhibition with L-NAME 
impeded the acute arterial blood pressure attenuation. Moreover, eNOS protein levels of 
isolated aortic rings, extracted from EGb 761 pretreated rats, were clearly elevated 
(Figure 26). Hence, the author concludes that the acute attenuation of the arterial blood 
pressure due to EGb 761 treatment is more likely eNOS regulated, than caused by a 
reduction of oxidative stress as claimed by Sasaki et al..145  
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In consideration of the increased tissue damage after treatment of EGb 761 prior to 
warm IR, at least two reasons can be assumed. On the one hand, the systemic blood 
pressure drop, mediated by the NO/GC pathway, leads to severe microcirculatory 
disturbances resulting in reduced liver blood flow and microvessel thrombosis. On the 
other hand, direct cytotoxicity, which is most likely caused by the generation of 
peroxynitrite. Since iNOS activation is known to be upregulated during IRI,44 in this 
case both, iNOS and eNOS, might contribute to elevated NO levels thus favoring 
peroxynitrite generation. 
In conclusion, EGb 761 administration prior to warm IR of the liver has no beneficial 
effect, on the contrary, it is rather toxic. Therefore, this project did not focus in more 
detail on the IR process, as the therapeutic use of EGb 761 in this model is not 
appropriate. Hence, acute hypotension after EGb 761 administration was the main 
interest, as it might be crucial for impaired tissue damage due to constricted 
microcirculation during reperfusion. Here, it could be demonstrated that EGb 761 
upregulates eNOS activation, which is responsible for acute hypotension after 
intravenous administration (Figure 51). On the contrary, it can be hypothesized that the 
beneficial therapeutic effects of EGb 761 in vascular diseases might be also related to 
its molecular function on eNOS regulation. 
 
Figure 51 Concluding results of intravenous EGb 761 application in vivo. 
 
However, the mode of EGb 761 application seems to be important, as oral or 
intraperitoneal administrations did not worsen hepatic tissue injury.146-148 Studies on the 
pharmacokinetics of oral EGb 761 administration revealed that the bioavailability of the 
flavonol glycosides is either relatively low or the metabolic biotransformation is high. 
However, ginkgolide A and B as well as bilobalides were found to be bioavailable, 
despite high urinary excretion.149 This recommends that the spectrum of active 
components of EGb 761 is strongly influenced by way of administration and thus is 
arbitrative for the toxicological impact of EGb 761 in vivo.  
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4.2 XANTHOHUMOL AND 3-HYDROXYXANTHOHUMOL 
 
In the 1990th, epidemiological studies indicated that the French population suffers a 
relatively low incidence of coronary heart diseases despite high intake of saturated fat. 
It was assumed that the comparable high wine consumption of the French population is 
responsible for this phenomenon, today also referred to as “French paradox”.9, 150 In the 
following years, research indicated that the polyphenol resveratrol is a main contributor, 
as it is in particular present in grapes, thus in red wine.151, 152 
In recent years, several dietary polyphenols like epigallocathechine, quercetin, taxifolin, 
rutin and isoliquiritigenin to name a few, which are mainly found in fruits, vegetables, 
tea, grains and legumes, gained interest due to their health benefits and protective 
effects in different human disease models.2, 7 Their antioxidant activities are assumed to 
be mainly responsible for these effects.8, 96 In the oxidative stress driven hepatic IR 
model, several flavonoids and polyphenols showed beneficial effects in preventing 
hepatic tissue damage.99-103 
The antioxidant activities of XN, the principal prenylated flavonoid of the hop plant, 
and of OH-XN, a metabolite occurring during XN biotransformation, were published in 
vitro by different groups.10, 107, 128 In this work the antioxidant activity of both 
compounds were verified to provide a basis for following in vivo experiments. Both, 
XN and OH-XN, showed strong inhibitory activities on ROS production in the 
xanthine/xanthine-oxidase cell-free system (Figure 28; Figure 29). The IC50 of XN 
(15µM) in comparison to the work of Gerhäuser was slightly different, what might be 
due to differences in the method applied.10 Interestingly, in the cellular model (H2FDA 
assay) OH-XN showed a significant higher inhibitory capacity on oxidative stress 
induced by H2O2 compared to XN (Figure 30). OH-XN even exceeded the activities of 
the well-known antioxidant N-acetylcysteine (NAC).153 Structural differences of both 
compounds could explain these results, as structural activity relationship (SAR) studies 
for other polyphenolics showed that the amount of hydroxyl substituents and their 
specific arrangement affects their antioxidant activity. More precisely, an ortho-
diphenoxyl functionality and an added hydroxyl group, as seen for OH-XN, did increase 
the antioxidant potential of these compounds.108-110 
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The activation of the redox sensitive transcription factor NF-κB was suggested to be 
relevant for hepatic IRI, as it upregulates the expression of different proinflammatory 
genes.66, 154 Oral treatment of rats with green tea extract, which contains high levels of 
polyphenols, has demonstrated to inhibit NF-κB binding activity in hepatic warm IR.45 
Influences of XN on NF-κB were previously shown in vitro in different cancer cell 
models.117, 118 In this study, XN and OH-XN reduced NF-κB activation dose-
dependently in a NF-κB reportergene assay (Figure 31). Interestingly, the IC50 of the 
compounds (XN = 35 µM; OH-XN = 13 µM) did correlate with their antioxidant 
activity in the cellular model (Figure 30), since OH-XN displayed a higher potential in 
both models. This could prove that NF-κB activation correlates with oxidative stress, as 
already shown in several models.15 Moreover, the author illustrates for the first time that 
XN is able to inhibit NF-κB DNA binding activity in vivo in the complex process of 
warm IR, regardless of the duration of reperfusion (Figure 32; Figure 33). It is proposed 
in literature that hepatic NF-κB activation induced by IR correlates with the severity of 
tissue damage, thus, its inhibition is beneficial.33, 66, 154, 155 Surprisingly, the tissue 
damage as indicated by the release of liver enzymes (AST, ALT) in the blood 
circulation, did not correlate with NF-κB inhibition after XN treatment in warm IR, 
instead levels were unaltered (Figure 34; Figure 35). Eventually, this could be an 
indication for the critical ambiguous role of NF-κB in the liver, since it is unlikely that 
XN inhibits NF-κB selectively in Kupffer cells, which are assumed to be mainly 
responsible for the transcription of proinflammatory mediators.24, 59, 60 Therefore, the 
isolated cold IR model was chosen for further analysis of this complex menchanism, as 
extrahepatic factors such as interference with blood constituents as well as interactions 
with other organs can be excluded. Hence, the impact of the substances can be solely 
investigated on the liver. 
Regarding their activity on the antioxidant system, XN and OH-XN treatment before 
cold IR displayed an impressive restoration of the superoxide dismutase (SOD) levels, 
which were strongly diminished by IR (Figure 37). SOD is an endogenous enzyme, 
which accounts for detoxification of a major proportion of the highly reactive 
superoxide anion radical in the liver tissue. The administration of SOD derivatives in 
the hepatic IR process has previously demonstrated to be protective.156 Moreover, 
administration of the endogenous, non-enzymatic antioxidant GSH in different IR 
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models showed beneficial effects regarding the hepatic tissue injury.3, 157                  
Both compounds were able to abrogate decreased GSH levels induced by cold IR 
(Figure 36). Furthermore, XN and OH-XN inhibited JNK activation slightly, which 
confirmed their impact on the antioxidant system, since JNK activation occurs primarily 
in the reperfusion phase in response to ROS (Figure 43).22, 136 Lipid peroxidation is a 
parameter indicating oxidative damage to membrane lipids by ROS, which is assumed 
to be mainly involved in IRI. Here, no differences could be seen in the TBARS assay 
applied (Figure 38). This confirms the view of others, that lipid peroxidation is not 
necessarily an appropriate marker in the model of hepatic IRI.158 Moreover, the TBARS 
assay determines malondialdehyde (MDA), which is a degradation product of 
polyunsaturated fatty acids. Its specificity toward other compounds than MDA is 
questionable,159 although, it is the most widely performed assay to measure lipid 
peroxidation. 
NF-κB activation was strongly reduced after XN treatment in cold IR, whereas, OH-XN 
did not have any impact (Figure 39), although its antioxidant activities were apparent as 
mentioned above. Interestingly, similar results were observed when the polyphenol 
curcumin is reduced to tetra-hydrocurcumin, which resulted in the loss of NF-κB 
inhibition although the antioxidant activity was still intact.160 Moreover, it was 
demonstrated by Dell’Agli et al. that lipophilic catechin analogues inhibit NF-κB 
activity more potently than hydrophilic ones.161 Furthermore, it can be assumed that the 
structural differences, which are associated with higher hydrophilicity of OH-XN, may 
impact the cellular uptake and the susceptibility for metabolic biotransformation, thus 
influencing the biological impact of OH-XN. 
To investigate the way of NF-κB inhibition, the impact of XN and OH-XN on the Akt 
pathway was elucidated. Akt is an important upstream activator of NF-κB.134 Activation 
leads to IKK phosphorylation in the cytoplasm, which in turn is able to phosphorylate 
IκB, thus, activating the translocation of NF-κB into the nucleus where it starts gene 
transcription. It has recently been reported in vitro that XN represses Akt 
phosphorylation.88 Here, Akt inhibition of both phosphorylation domains (Thr-308; Ser-
473) has been shown for XN (Figure 40; Figure 41), whereas OH-XN attenuated only 
phosphorylation on Ser-473. However, full activation of Akt requires phosphorylation 
of both domains, though it has been postulated that the first phosphorylation step on the 
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Thr-308 domain is the main activating event of Akt.134 Thus, it can be assumed that the 
inhibition of Ser-473 phosphorylation by OH-XN results only in minimal Akt inhibition 
since Thr-308 is still phosphorylated. These results suggest that NF-κB inhibition by 
XN in cold IR is, at least in part, regulated by an Akt inhibition. However, the activation 
of NF-κB via ROS has to be challenged, since OH-XN showed no effect, although an 
impressive GSH and SOD upregulation was observed. Karin and colleagues confirmed 
these results as they found that endogenously produced ROS do not lead to NF-κB 
activation.153 
Additionally, Akt is a central regulator of apoptosis as it inactivates proapoptotic 
molecules of the Bcl-2 family like Bad, thereby, antiapoptotic members such as Bcl-2 
and Bcl-xl are activated.134 Constitutively active Akt induced via adenoviral gene 
transfer, has shown to be protective as apoptosis is inhibited in the liver subjected to 
IR.162 In contrast, inhibition of Akt with wortmannin is associated with reduced 
protection from hepatic IR.66 In this work we could demonstrate that Akt inhibition by 
XN treatment correlates with diminished levels of the antiapoptotic protein Bcl-xl 
(Figure 42) as well as with an activation of caspase-3 (Figure 44). Caspases are 
intracellular cysteine proteases that mediate inflammation and cell-death. Caspase-3 in 
particular is the main effector molecule of apoptosis and a selective inhibition in the IR 
process effectively reduced hepatic IRI.133 Eventually, liver tissue damage, as measured 
by the liver enzymes, was elevated by XN treatment and remained unchanged by OH-
XN (Figure 47), furthermore the TNF-α levels correlated with the tissue damage 
(Figure 45). 
 
In conclusion (Figure 52), these results indicate that the flavonoids Xanthohumol and 3-
Hydroxyxanthohumol in the biological relevant model of hepatic IR, which is oxidative 
stress driven, do not improve tissue injury despite their extensive antioxidant activities. 
Moreover, based on these data, NF-κB activation in cold IR seems to be, at least in part, 
regulated over the Akt pathway, as its inhibition by Xanthohumol correlates with NF-
κB attenuation. In contrast, the oxidative stress driven NF-κB activation is rather 
questionable, since 3-Hydroxyxanthohumol did not inhibit NF-κB activation at all, 
although its impact on the antioxidant system is impressive. Interestingly, tissue damage 
induced by IR does not correlate with NF-κB activation in this study. On the one hand 
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that might be due to cell-unspecific NF-κB inhibition in the entire liver, resulting in 
abolished proliferative i.e. protective properties of hepatocytes. On the other hand, NF-
κB inhibition over the Akt pathway goes along with decreased levels of antiapoptotic 
protein levels, which could be responsible for elevated tissue damage followed by IR as 
well. 
 
 
Figure 52 Concluding results of the impact of XN and OH-XN in hepatic IRI. 
 
However, although the antioxidant activities of flavonoids are undisputable, the 
bioavailability of dietary flavonoids after oral consumption is limited due to the 
extensive metabolisation.163 Therefore, it is questionable whether the beneficial     
impact of flavonoid-rich nutrients can be solely referred to the flavonoids and their 
antioxidant activity. Concluding, flavonoids do not consequently warrant beneficial 
therapeutic use in oxidative stress driven injury models, as verified here for the hepatic 
IR injury. 
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4.3 NF-κB DECOY NANOPARTICLES 
 
The NF-κB signal transduction pathway is assumed to be crucial during IR in the liver, 
as it has long been thought that its activation induces purely the expression of several 
proinflammatory cytokines such as TNF-α and IL-1 as well as adhesion molecules like 
ICAM-1, which contribute to hepatic tissue injury.15, 31 The idea of targeting Kupffer 
cells exclusively derives from several studies, which revealed in recent years that NF-
κB function is more likely different depending on the liver cell-type addressed and 
potentially opposing in nature. It is assumed that NF-κB in hepatocytes induces 
predominantly antiapoptotic proteins and participates in regeneration and proliferation, 
hence, in liver protection.22, 59 However, NF-κB activation in Kupffer cells is assumed 
to be responsible for the inflammatory response after IR.24 Alternatively, it was also 
proposed that TNF-α and IL-6 release of Kupffer cells driven by NF-κB activation, is 
responsible for hepatocyte proliferation and regeneration.15, 62 Eventually, global 
modulations of NF-κB have previously shown that the desired therapeutic effect cannot 
be achieved with cell-unspecific targeting.54-58 
Dr. Florian Hoffmann introduced gelatin NP as a new tool in his recent Ph.D. thesis, 
which selectively targets Kupffer cells. Administration of NF-κB oligonucleotides 
decoy loaded to gelatin NP in vivo prior to warm IR (1 h / 2 h) abolished NF-κB 
activation and reduced TNF-α release as well as expression. Asthonishingly, liver tissue 
damage remained unaltered. Eventually, Dr. Hoffmann hypothesized that NF-κB 
activation in Kupffer cells is not crucial for liver damage.  
Based on these interesting results, we wanted to elucidate the role of NF-κB in a model 
more closely related to the transplantation process, the cold IR process. This model is 
advantageous in our case for various reasons. On the one hand it solely focus on the 
liver. Interventions with blood constituents and influences of other organs can be 
avoided. Moreover, the tissue damage does entirely derive from the liver and hepatic 
factors. On the other hand, Kupffer cells, which are the main target of NF-κB decoy NP 
treatment, are vigorously activated during cold IR. That accounts to be a major 
difference compared to the warm IR model.15 
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The suitability of the application mode was proven by confocal laser scanning 
microscopy and revealed selective Kupffer cell targeting in the isolated cold IR model 
(6 h / 2.5 h). Parenchymal cells were not affected (Figure 48). NF-κB binding activity 
was analyzed by EMSA, which determines the NF-κB levels of whole liver tissue 
homogenates. As shown in Figure 49, NF-κB decoy-NP treatment completely abolished 
NF-κB activation. Interestingly, selective NF-κB inhibition in Kupffer cells in the cold 
IR model did not improve tissue damage, instead hepatic injury remained unaltered 
(Figure 50). However, Dr. Florian Hoffmann recently demonstrated that postischemic 
hepatic tissue injury followed by long reperfusion periods (24 h) increased markedly 
after decoy-NP treatment. 
 
Based on these data two hypothesis are volunteered:  
First, NF-κB activation in Kupffer cells is not responsible for acute hepatic tissue injury 
induced by either warm or cold IR. Although Lentsch et al. have recently shown that 
NF-κB activation in Kupffer cells correlates with hepatic tissue injury, selective NF-κB 
inhibition in Kupffer cells and direct correlation with hepatic injury, remains to be 
proven.60 Indeed, it can be hypothesized that Kupffer cells seem to participate in other 
ways to early tissue damage, as their depletion has shown several times to be beneficial 
in IR.61 Thus, other pathways than the NF-κB signal transduction cascade might be 
more likely implicated. Jaeschke et al. assumed that oxidative stress derived from the 
postischemic ROS release by Kupffer cells, which are the main sources of vascular 
ROS formation, is crucial for the subsequent injury cascade, thus for hepatocellular 
injury.1 Since direct cytotoxicity of ROS is quantitatively insufficient to explain severe 
injury during reperfusion,32 it was proposed by Bilzer and Gerbes that ROS mediate 
TNF-α, IL and PAF release of endothelial cells and monocytes, and modulate mitogen-
activated protein kinases (e.g. JNK), which might also be implicated in tissue injury 
mediated by Kupffer cells.3 However, it should be kept in mind that the essential role of 
Kupffer cells in the initial phase of reperfusion injury allows several pathways to be 
involved, which are not necessarily NF-κB regulated. 
Second, NF-κB activation in Kupffer cells contributes to late tissue protection after 
hepatic IR. Whether Kupffer cells directly impact liver protection or indirectly by 
hepatocyte NF-κB activation, via TNF-α and IL-6 release, is not yet clear. However, 
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the latter is more likely, since NF-κB is downregulated in the entire liver, as mentioned 
above. Thus, downregulation of hepatocyte derived NF-κB would explain tissue injury 
after long periods of reperfusion, as its activation was reported to be responsible for 
regeneration and proliferation.120  
 
 
Figure 53 Role of NF-κB in Kupffer cells. 
 
In conclusion, the role of NF-κB in Kupffer cells seems to be more complicated than 
generally proposed. Kupffer cells seem not to participate in acute IR damage triggered 
by NF-κB, other pathways are more likely to be involved (Figure 53). Moreover, 
hepatocellular protection after longer reperfusion periods seems to be an intrinsic 
function of NF-κB in Kupffer cells during IRI, whereas its detailed mechanism with 
special consideration of hepatocytes remains to be elucidated. 
  
SUMMARY 
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In the present study different approaches, from natural to synthetic origin, were 
investigated in the multifunctional IR model of the liver. First, EGb 761 (a) – a 
standardized extract of several ingredients, second, Xanthohumol (b) – a single 
compound of the hop plant and 3-Hydroxyxanthohumol a biotransformation product, 
third, NF-κB decoy-NP (c) – a tool targeting selectively the transcription factor NF-κB 
exclusively in Kupffer cells. 
 
a. Interestingly, EGb 761 did not show beneficial effects on hepatic IRI, this study 
rather revealed that intravenous administration implicates crucial toxic potential. 
Coincidently, impressive acute hypotension was observed in that line, caused by 
eNOS activation triggered by the phosphoinositide 3-kinase (PI3K)/Akt 
pathway. The toxic effects might depend on the administration mode of EGb 
761 and are assumed to result, at least in part, from systemic blood pressure drop 
which led to a decline in hepatic microcirculation.  
 
b. The flavonoids Xanthohumol and 3-Hydroxyxanthohumol have shown to be 
potent antioxidants in vitro and in the complex oxidative stress driven model of 
hepatic IR. Interestingly, Xanthohumol inhibited NF-κB activation by the Akt 
pathway, which correlates with downregulation of antiapoptotic and 
upregulation of proapoptotic markers. Since cell unspecific NF-κB inhibition 
with Xanthohumol is more likely to happen, it might explain that NF-κB 
inhibition results in increased tissue injury. In contrast, 3-Hydroxyxanthohumol 
had no impact on the NF-κB pathway, eventually tissue injury remained 
unaltered. In conclusion, flavonoids do not necessarily warrant beneficial usage 
due to their antioxidant capacity, more attention has to be paid on other 
pathways involved. 
 
c. Selective NF-κB inhibition in Kupffer cells with decoy-NP was achieved in an 
isolated model of hepatic IR. NF-κB activation was abolished without affecting 
tissue injury. Therefore, the NF-κB pathway derived from Kupffer cells does not 
contribute to acute IR injury. However, its impact on regeneration and 
proliferation of the liver is favored. 
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